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GENERAL INTRODUCTION 
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ADENOSINE 
Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar 
molecule (ribofuranose) via a β-N9-glycosidic bond (Figure 1). 
 
 
 
 
 
 
 
 
                                       Figure 1 – Chemical structure of Adenosine 
 
Adenosine is an endogenous nucleoside-signalling molecule, which, by acting on 
specific membrane receptors produces a number of physiological and 
pathophysiological effects in both the central nervous system and peripheral organs. 
Under normal conditions, adenosine is continuously formed intracellularly as well as 
extracellulalry. The intracellular production is mediated either by an intracellular 5’-
nucleotidase, which dephosphorylates AMP or by hydrolysis of S-adenosyl-
homocysteine (Fredholm et al., 2001). Adenosine generated intracellular is transported 
into the extracellular space mainly via specific bi-directional transportes through 
facilitated diffusion that efficiently evens out the intra-and extracellular levels of 
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adenosine. The dephosphorylation of extracellular AMP to adenosine, mediated by 
ecto-5’-nucleotidase, is the last step in the enzymatic chain that catalyzes the breakdown 
of extracellular adenine nucleotides, such as ATP, to adenosine. Ectonucleotidases 
include ectonucleoside triphosphate diphosphohydrolase which can hydrolyze ATP or 
ADP, ectonucleotide pyrophosphatase/phosphodiesterases, alkaline phosphatases and 
5’-nucleotidases (Zimmermann, 2000). When adenosine levels in the extracellular space 
are high, adenosine is transported into cells by means of transportes. It is then 
phosphorylated to AMP by adenosine kinase or degraded to inosine by adenosine 
deaminase. Adenosine deaminase, but not adenosine kinase, is also present in the 
extracellular space (Fredholm et al., 2001). Another potential source of extracellular 
adenosine is cAMP, which can be released from neurons and converted by extracellular 
phosphodiesterases into AMP and thereafter by an ecto-5’-nucleotidase to adenosine. 
The transport of adenosine by facilitated diffusion is equilibrative and bidirectional, 
meaning that the net transport of adenosine either into or out of the cell depends upon 
the adenosine concentration gradient in both sides of the membrane. Inhibition of 
adenosine transport can, therefore, inhibit either adenosine release or adenosine uptake, 
depending upon the intra- and extracellular levels of adenosine (Baraldi et al., 2008). 
However, since the extracellular formation of adenosine from released adenine 
nucleotides constitutes a second source of adenosine, which is not affected by transport 
inhibition, the transport inhibitors usually cause an icrease in the extracellular adenosine 
levels. Under hypoxic and ischemic conditions there is a marked increase in 
cytoplasmatic adenosine leading to an intense release of adenosine, which is inhibited 
by adenosine uptake inhibitors (Parkinson et al., 2002). 
Excitatory amino acid-mediated release of adenosine is certainly involved; however, of 
greater importance is probably the fact that whenever intracellular levels of adenine 
nucleotides fall as a result of excessive energy use, the intracellular levels of adenosine 
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will rise dramatically (Fredholm et al., 2001). For example, following hypoxia there is a 
decrease of intracellular ATP, accompanied by an accumulation of 5’-AMP and 
subsequently adenosine: The nucleoside is thereafter transported into the extracellular 
space via the transporters. Furthermore, when the intracellular level of adenosine is very 
high, adenosine simply diffuses out of cells. Direct release of intracellular adenine 
nucleotides, such as ATP, that is thereafter converted extracellularly by ecto-ATPase 
and ecto-ATPdiphosphohydrolase (ecto-apyrase) to AMP and dphosphorylated by ecto-
5’-nucleotidase to adenosine, should also be considered (Zimmermann et al., 2000). 
Adenosine is neither stored not released as a classical neurotransmitter since it does not 
accumulate in synaptic vescicles, being released from the cytoplasm into the 
extracellular space through a nucleoside transporter. The adenosine transportes also 
mediate adenosine reuptake , the direction of the transport being dependent upon the 
concentration gradient at both sides of the membrane (Fredlhom et al., 2001). Since it is 
not exocytotically released, adenosine behaves as an extracellular signal molecule 
influencing synaptic transmission withiìout itself being a neurotransmitter, i.e. 
modulates the activity of the nervous system at celluar level presynaptically by 
inhibiting or facilitating transmitter release, postsynaptically by hyperpolarizing or 
depolarizing neurons and/or exerting nn-synaptic effects. Adenosine, therefore, belongs 
to the group of neiromodulators. 
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Adenosine receptors 
Four adenosine receptor (AR) subtypes (A1, A2A, A2B, and A3) have been cloned and 
pharmacologically characterized, all of which are G protein-coupled receptors (GPCRs). 
(Figure.2) 
Adenosine receptors can be distinguished according to their preferred mechanism of 
signal transduction: A1 and A3 receptors interact with pertussis toxin-sensitive G 
proteins of the Gi and Go family; the canonical signaling mechanism of the A2A and of 
the A2B receptors is stimulation of adenylyl cyclase via Gs proteins. In addition to the 
coupling to adenylyl cyclase, all four subtypes may positively couple to phospholipase 
C via different G protein subunits (Fredholm et al, 2001; Ciruela et al, 2010). (Table.1) 
Furthermore it has been demonstrated that adenosine, through interaction with 
adenosine receptors,  mediated phosphorylation of MAPK kinase family.  
Considering the overall protein structure, ARs display the topology typical of GPCRs. 
Sequence comparison between the different GPCRs revealed the existence of different 
receptor families sharing no sequence similarity even if specific fingerprints exist in all 
GPCR classes. However, all these receptors have in common a central core domain 
consisting of seven transmembrane helices (TM1-7), with each TM composed of 20–27 
amino acids, connected by three intracellular (IL1, IL2, and IL3) and three extracellular 
(EL1, EL2, and EL3) loops. Two cysteine residues (one in TM3 and one in EL2), which 
are conserved in most GPCRs, form a disulfide link which is possibly crucial for the 
packing and for the stabilization of a restricted number of conformations of these seven 
TMs. Aside from sequence variations, GPCRs differ in the length and function of their 
N-terminal extracellular domain, their C-terminal intracellular domain, and their 
intracellular loops. Each of these domains provides very specific properties to these 
receptor proteins. Particularly, consensus sites for N-linked glycosylation exist on the 
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extracellular regions of ARs, although the precise location of the sites for this post-
translational modification varies amongst the AR subtypes. The carboxyl-terminal tails 
of the A1AR, A2BAR, and A3AR, but not A2AAR, possess a conserved cysteine residue 
that may putatively serve as a site for receptor palmitoylation and permit the formation 
of a fourth intracellular loop (Moro et al., 2005). 
The A1AR, A2BAR, and A3AR are very similar in regard to the number of amino acids 
composing their primary structure, and in general, these AR subtypes are among the 
smaller members of the GPCR family. For example, the human homologs of the A1AR, 
A2BAR, and A3AR consist of 326, 328, and 318 amino acid residues, respectively. 
Conversely, the human A2AAR is composed of 409 amino acids. It should be noted that 
the size of ARs deduced from their primary amino acid structure frequently is not 
consistent with the mass estimated by polyacrylamide gel electrophoresis of the 
expressed proteins. The post-translational glycosylation of ARs, which may vary in a 
cell type-dependent fashion, likely accounts for these discrepancies. The human A1AR 
and human A3AR display 49% overall sequence identity at the amino acid level, while 
the human A2AAR and human A2BAR are 45% identical (Fredholm et al, 2001).  
 
 
 
 
 
 
 
 
 
                                       Figure.2  G protein-coupled receptors (GPCRs). 
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Table.1 
 
Adenosine receptors in the brain. 
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A1 adenosine receptors 
The A1 receptor is widely expressed throughout the body, having its highest expression 
in the brain, spinal cord, atria and adipose tissue (Ciruela et al., 2010). Via adenosine 
A1ARs, adenosine reduces heart rate, glomerular filtration rate, and renin release in the 
kidney; it induces bronchoconstriction  and inhibits lipolysis (Elzein and Zablocki, 
2008). Adenosine A1Rs can be coupled to different pertussis toxin-sensitive G proteins, 
which mediate inhibition of adenylate cyclase  and regulate calcium and potassium 
channels, as well as inositol phosphate metabolism (Fredholm et al., 2001). A1ARs and 
A2AARs are primarily responsible for the central effects of adenosine (Dunwiddie and 
Masino, 2001). In addition to their postsynaptic locations in different brain regions, 
A1ARs can be found presynaptically and modulate neurotransmitter release. Presynaptic 
A1ARs are the prototype of GPCRs, the stimulation of which decreases the probability 
of neurotransmitter release. The main mechanism of A1AR-mediated inhibition of 
exocytosis is a direct inhibitory effect on voltage-dependent Ca2+ channels (Moore et 
al., 2003). A1AR displays two different affinities for agonist, which have classically 
been attributed to a different coupling to heterotrimeric G proteins. According to this 
two independent site model, coupled receptor–G protein complexes display high affinity 
for agonists and uncoupled receptors display low affinity. The reported cluster-arranged 
cooperative model predicts that the high- and low-affinity sites are a consequence of the 
negative cooperativity of agonist binding and do not seem to be related to the content of 
G protein-coupled or –uncoupled receptors (Franco et al., 1996). Like other GPCR 
members, A1AR expression is regulated in response to agonist or antagonist stimulation. 
Desensitization of A1ARs has been described in intact animals and in cell cultures. 
Prolonged administration of A1AR agonists to animals leads to functional 
desensitization of A1ARs in guinea pig heart, rat adipocytes, rat atrial muscle, and rat 
brain (Moro et al., 2006). The reduced functional response is attributable to a net loss of 
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A1ARs or down-regulation, a decrease in the proportion of A1ARs displaying the high-
affinity state for agonists, and a decrease in the content of Gi proteins. The loss of 
binding sites on the cell membrane owing to internalization of A1ARs is a slower event. 
Ser/Thr phosphorylation seems to be related to short-term clustering and 
desensitization, as well as long-term internalization of A1ARs (Ciruela et al., 1997). 
 
A2A adenosine receptors 
The A2AAR exists in a wide variety of organs including major peripheral tissues (e.g., 
liver, heart, lung, and the immune system) and the central nervous system (CNS) (Lee et 
al., 2003). In the developing rat brain, expression of the A2AAR is transiently regulated 
in various areas (e.g., the striatum, cortex, and hippocampus), perhaps implying a role 
of adenosine in neuronal development. Soon after neurogenesis, the A2AAR is highly 
expressed by striatal neurons and co-localizes with the D2 dopamine receptor in 
GABAergic striatopallidal neurons (Ferrè et al., 2008). In addition to the intense 
expression in the striatum, low levels of A2AAR are found in many brain regions (e.g., 
the cortex and hippocampus) and it has been suggested that adenosine acting at the 
A2AAR regulates important neuronal functions including neuronal protection and 
synaptic transmission (Ferrè et al., 2008). Regulation of A2AAR gene expression is 
therefore likely to play an important role in neuronal development, basal ganglia 
activity, and many other peripheral functions. In the CNS, l-DOPA enhanced the gene 
expression of the striatal A2AAR in 6-OHDA-lesioned rats (Tomiyama et al., 2004). 
Treatment with an antagonist of the NMDA receptor (memantine) was also reported to 
elevate the transcript level of striatal A2AARs (Marvanova and Wong, 2004). The 
adenosine A2AAR couples primarily to members of the Gs family. Like other GPCRs it 
can also interact with other G proteins if the receptor is very over-expressed, but the 
evidence for such coupling in vivo is not compelling. In striatum the A2AAR interacts 
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with Golf proteins (Corvol et al., 2001). It is not known if there are significant 
differences in receptor affinity or in signaling dependent on which of the two partners 
(or which variant of Gs) the receptor interacts with. There are instances where other G 
protein pathways have been implicated, and it will be important to determine if this 
alternate coupling is a regulated process, for example via phosphorylation. There is no 
compelling reason to assume that this GPCR coupling to members of the Gs family 
would signal in anything but a canonical way. Thus, most effects are probably due to 
activation of adenylyl cyclase and generation of cAMP. The A2AAR can recruit β-
arrestin via a GRK-2 dependent mechanism (Khoa et al., 2006). This is influenced by 
activation of cytokine receptors, which cause reduced desensitization of the A2AAR 
(Khoa et al., 2006).  
One key target of PKA is the cAMP responsive element-binding protein (CREB) which 
is critical for many forms of neuronal plasticity as well as other neuronal functions 
(Josselyn and Nguyen, 2005). Phosphorylation of CREB at Ser133 by PKA activates 
CREB and turns on genes with cAMP responsive elements (CRE sites) in their 
promoters. One important feature of CREB is that it is a point of convergence for the 
cAMP/PKA and MAPK pathways. Stimulation of the A2AARs counteracts the 
inhibition of neurite outgrowth due to MAPK blockade (Cheng et al., 2002). 
Stimulation of the A2AAR alone also activates the Ras/Raf-1/MEK/ERK signaling 
through PKA-dependent and PKA-independent pathways via Src- and Sos- mediated 
mechanisms, respectively (Schulte and Fredholm, 2003). Interestingly, 
phosphorylation/activation of CREB has been shown to compete with nuclear factor-κB 
(NFκB) p65 for an important co-factor, CBP. Phosphorylated CREB was therefore 
proposed to mediate the anti-inflammatory effect of the A2AAR receptor and inhibition 
of NFκB by A2AAR activation during acute inflammation in vivo was demonstrated 
(Fredholm et al., 2007).  
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An interesting observation is that activation of A2AAR receptor facilitates activities of 
adenosine transporters via a PKC-dependent pathway in the hippocampus, and thus 
reduces the level of extracellular adenosine available for A1AR activation (Pinto-Duarte 
et al., 2005). In addition, PKC was shown to play a key role in mediating the 
enhancement of noradrenaline release by the A2AAR in rat tail artery (Fresco et al., 
2004). Activation of multiple signaling pathways by the A2AAR appears to contribute to 
its diverse and complex functions in various tissues. 
 
 
A2B adenosine receptors 
A2BAR mRNA was originally detected in a limited number of rat tissues by Northern 
blot analysis, with the highest levels found in cecum, bowel, and bladder, followed by 
brain, spinal cord, lung, epididymis, vas deferens, and pituitary. The use of more 
sensitive reverse transcriptase-polymerase chain reaction techniques revealed a 
ubiquitous distribution of A2BAR (Spicuzza et al., 2006). mRNA encoding A2BAR was 
detected at various levels in all rat tissues studied, with the highest levels in the 
proximal colon and lowest in the liver. In situ hybridization of A2BARs showed 
widespread and uniform distribution of A2BAR mRNA throughout the brain (Dixon et 
al., 1996).  
Pharmacological identification of A2BARs, based on their low affinity and characteristic 
order of potency for agonists, also indicates a widespread distribution of A2BARs. In 
brain, functional A2BARs are found in neurons  and glial cells. Although there is no 
evidence that A2BAR are present in microglia, there is ample data that show that they 
are expressed in astrocytes and in different glioma cell lines (Fiebich et al., 1996). The 
expression of A2BARs in glial cells, which represent a majority of the brain cell 
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population, can explain the original observation that slices from all brain areas 
examined showed an adenosine-stimulated cAMP response. 
Functional A2BARs have been found in fibroblasts and various vascular beds, 
hematopoietic cells, mast cells, myocardial cells, intestinal epithelial and muscle cells, 
retinal pigment epithelium, endothelium, and neurosecretory cells (Gessi et al., 2005). 
Although activation of adenyl cyclase is arguably an important signaling mechanism for 
A2AARs, this is not necessarily the case for A2BARs, as other intracellular signaling 
pathways have been found to be functionally coupled to these receptors in addition to 
adenyl cyclase. In fact activation of adenosine A2BARs can increase phospholipase C in 
human mast cells and in mouse bone marrow-derived mast cells. A2BAR activation also 
elevates inositol triphosphate (IP3) levels, indicating this receptor can couple also to 
Gq-proteins. A2BARs have been implicated in the regulation of mast cell secretion  and, 
gene expression, intestinal function, neurosecretion, vascular tone and in particular 
asthma (Varani et al., 2005). 
 
 
A3 adenosine receptors 
The A3 adenosine receptor (A3AR) is the only adenosine subtype which was cloned 
before its pharmacological identification. It was originally isolated as an orphan 
receptor from rat testis, having 40% sequence homology with canine A1 and A2A 
subtypes (Meyerhof et al., 1991) and was identical with the A3AR later cloned from rat 
striatum (Zhou et al., 1992). Homologs of the rat striatal A3AR have been cloned from 
sheep and human, revealing large interspecies differences in A3AR structure. For 
example, the rat A3AR presents only 74% sequence homology with sheep and human 
A3AR, while there is 85% homology between sheep and human A3AR. This is reflected 
in the very different pharmacological profiles of the species homologs, especially in 
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terms of antagonist binding that has made characterization of this adenosine subtype 
difficult. Recently equine A3AR has been cloned and pharmacologically characterized. 
Sequencing of the cDNA indicated that it has a high degree of sequence similarity with 
that of other mammalian A3AR transcripts, including human and sheep (Brandon et al., 
2006). 
The A3AR has been mapped on human chromosome 1p21-p13 (Atkinson et al., 1997) 
and consists of 318 aminoacid residues. Murrison et al. (1996) determined that the 
A3AR gene contains 2 exons separated by a single intron of about 2.2 kb. The upstream 
sequence does not contain a TATA-like motif, but it has a CCAAT sequence and 
consensus binding sites for SP1, NF-IL6, GATA1 and GATA3 transcription factors. 
Involvement of the latter in transcriptional control of this gene would be consistent with 
a role of the receptor in immune function. The A3AR is a G-protein-coupled receptor 
(GPCR) characterized by its C-terminal portion facing the intracellular compartment 
and 7 transmembrane spanning domains. In contrast to other adenosine receptors, the C-
terminal region presents multiple serine and threonine residues, which may serve as 
potential sites of phosphorylation that are important for rapid receptor desensitization 
upon agonist application (Palmer & Stiles, 2000). Phosphorylation leads to a decrease 
of the number of receptors in the high-affinity state and a decrease of agonist potency to 
inhibit adenylyl cyclase activity. At the same time, the receptor is reversibly internalized 
in an agonist-dependent fashion (Trincavelli et al., 2002a). 
The A3AR has widely distributed its mRNA being expressed in testis, lung, kidneys, 
placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, proximal colon and eye of 
rat, sheep and humans. However, marked differences exist in expression levels within 
and among species. In particular rat testis and mast cells express high concentrations of 
A3AR mRNA, while low levels have been detected in most other rat tissues (Gessi et 
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al., 2008). Lung and liver have been found as the organs expressing high levels of 
A3AR mRNA in human, while low levels have been found in aorta and brain. Lung, 
spleen, pars tuberalis and pineal gland expressed the highest levels of A3AR mRNA in 
sheep. 
The presence of A3AR protein has been evaluated through radioligand binding, 
immunoassay or functional assay in a variety of primary cells, tissues and cell lines 
(Gessi et al., 2008). In the mouse brain a widespread, relatively low level of A3AR 
binding sites was found (Jacobson et al., 1993). Similar data were obtained in the rat 
and in gerbil and rabbit brain. Electrophysiological and biochemical evidence suggested 
the presence of A3ARs in the rat hippocampus and cortex, and functional studies also 
indicated its presence in the brain. In cardiomyocytes, there was no direct evidence of 
the presence of A3ARs  but several studies reported that it was responsible for 
cardioprotection in a variety of species and models, including isolated cardiomyocytes 
and isolated myocardial muscle preparations (Peart and Headrick, 2007). In lung 
parenchyma and in human lung type 2 alveolar-like cells (A549), the A3AR was 
detected through radioligand binding and immunohistochemical assays (Varani et al., 
2006).  
The classical pathways associated with A3AR activation are the inhibition of adenylyl 
cyclase activity, through the coupling with Gi proteins, and the stimulation of 
phospholipase C (PLC), inositol triphosphate (IP3) and intracellular calcium (Ca2+), via 
Gq proteins (Fredholm et al., 2001). However, more recently additional intracellular 
pathways have been described as relevant for A3AR signaling. For example, in the 
heart, A3AR mediates cardioprotective effects through ATP-sensitive potassium 
(KATP) channel activation. Moreover, it is coupled to activation of RhoA and a 
subsequent stimulation of phospholipase D (PLD), which in turn mediates protection of 
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cardiac myocytes from ischemia (Mozzicato et al., 2004). In addition, in different 
recombinant and native cell lines, A3AR is involved, like the other adenosine subtypes, 
in the modulation of mitogen-activated protein kinase (MAPK) activity (Schulte and 
Fredholm, 2003). A3AR signaling in Chinese Hamster Ovary cells transfected with 
human A3AR (CHO-hA3) leads to stimulation of extracellular signal-regulated kinases 
(ERK1/2). In particular, A3AR signaling to ERK1/2 depends on βγ release from 
pertussis toxin (PTX)-sensitive G proteins, phosphoinositide 3-kinase (PI3K), Ras and 
mitogen-activated protein kinase kinase (Schulte and Fredholm, 2003). It has been 
reported that A3AR activation is able to decrease the levels of PKA, a downstream 
effector of cAMP, and of the phosphorylated form of PKB/Akt in melanoma cells. This 
implies the deregulation of the Wnt signaling pathway, generally active during 
embryogenesis and tumorigenesis to increase cell cycle progression and cell 
proliferation (Fishman et al., 2002). Involvement of the PI3K/PKB pathway has been 
linked with preconditioning effects induced by A3AR activation in cardiomyocytes from 
newborn rats (Germack and Dickenson, 2005). An elegant study has recently 
documented a role of A3AR in cell survival signaling in resveratrol preconditioning of 
the heart. This study provides evidence that resveratrol preconditions the heart through 
the activation of adenosine A1 and A3AR, transmitting a survival signal through both 
the PI3K-Akt-Bcl2 and, only in the case of A3AR, cAMP response element-binding 
protein (CREB)-Bcl2 pathways (Das et al., 2005). Subsequently it has been 
demonstrated that CREB phosphorylation occurs through both Akt-dependent and -
independent signaling. Activation of PI3K-Akt-pBAD by A3AR has been observed 
recently in glioblastoma cells leading to cell survival in hypoxic conditions (Merighi et 
al., 2007). Further studies indicate that A3AR activation by interfering with PKB/Akt 
pathways can decrease interleukin-12 (IL-12) production in human monocytes (la Sala 
et al., 2005). Collectively, these findings demonstrate that several intracellular 
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mechanisms are involved following A3AR stimulation, the understanding of which may 
be essential and crucial for explaining the different aspect of its activation.  
 
Therapeutic potential of A3 adenosine receptors 
Neuroprotection versus neurodegeneration 
Considerable interest has been shown in understanding the involvement of A3AR in 
normal and pathological conditions of the CNS despite its low expression in the brain 
(Rivkees et al., 2000). Even though the function of A3AR in the CNS has been 
controversial in terms of protective versus toxic actions, actually several data point 
towards a neuroprotective effect. Firstly, a dual role of A3AR was described in a model 
of global ischemia in gerbils where acute preischemic administration of the agonist N6-
(3-iodobenzyl)-adenosine-5′-N-methylcarboxamide (IB-MECA) caused a severe 
depression of cerebral blood perfusion, worsening of neuronal damage and postischemic 
mortality, while its chronic administration induced a significant improvement of 
postischemic cerebral flow and neuron protection (Von Lubitz et al., 1994). In line with 
the results obtained after acute treatment, in rat cerebellar granule neurons high 
concentrations of Cl-IB-MECA were able to induce lactate dehydrogenase release, 
neuronal cell death and augmented glutamate-induced neurotoxicity through a pathway 
involving inhibition of cyclic AMP production (Sei et al., 1997). It was then observed 
that the effect of IB-MECA depended on the timing of treatment as administration of 
IB-MECA 20 min prior to transient middle cerebral ischemia increased the infarct size, 
whereas its addition 20 min after ischemia resulted in a significant decrease of damage, 
leading the authors to define the cerebroprotective effect of A3AR a “right thing at a 
wrong time” (Von Lubitz et al., 2001). It has been speculated that the deleterious effects 
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caused by acute preischemic treatment with IB-MECA were the consequence of a series 
of adverse events triggered immediately prior to the occlusion such as release of 
inflammatory mediators, breakdown of the blood–brain barrier integrity and Ca2+ influx. 
In contrast, the neuroprotective effects obtained when the A3 agonist treatment was 
performed following a focal insult were related to astrocyte activation or to a direct 
neuroprotective action (Von Lubitz et al., 2001). One of the main factors contributing to 
the overall neuroprotective profile of chronic treatment with A3AR agonists was found 
to be the reduction in post-ischemic expression of nitric oxide (NO) synthase, the 
enzyme involved in NO generation (Von Lubitz et al., 1999). Other beneficial effects 
associated with chronic A3AR stimulation were the increase of glial fibrillary acidic 
protein [(GFAP), astrocyte proliferation and preservation of the ischemia-sensitive 
microtubule-associated protein 2 (MAP-2) (Von Lubitz et al., 1999)]. Destructive and 
protective actions of A3AR stimulation have also been demonstrated in experiments in 
astroglial cells where Cl-IB-MECA at nanomolar doses was responsible for “trophic 
effects” related to reorganization of actin cytoskeleton, while in the micromolar range 
was a mediator of apoptosis ([Abbracchio et al., 1997], [Abbracchio et al., 2001], 
[Appel et al., 2001] and [Di Iorio et al., 2002]). Such apparently opposing effects have 
been reconciled by hypothesizing that adenosine-induced cell death that occurs during 
severe metabolic stress by A3AR activation might isolate the most damaged areas to 
favor those parts of the brain that still retained a chance for functional recovery, 
supporting the role of adenosine as a “retaliatory metabolite” (Von Lubitz, 1999). Later 
it was speculated that desensitization/down-regulation of the A3AR may be the basis of 
cytoprotection, suggesting a role for this receptor in induction of cell death (Trincavelli 
et al., 2002a). Recently a study performed in primary cortical cultures demonstrated that 
Cl-IB-MECA antagonized the hypoxia-mediated decrease in cell viability. Moreover, 
when given in vivo before focal cerebral ischemia, it reduced cerebral infarction while it 
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was inactive in A3 knock-out (A3KO) mice. Furthermore A3KO mice after ischemia 
presented an increase in cerebral infarction in comparison to wild-type animals 
suggesting that A3AR mediate a tonic protective condition during ischemia (Chen et al., 
2006b). In contrast, A3AR activation did not affect neuronal death triggered by kainate 
and cyclothiazide in primary cultures of cortical neurons (Rebola et al., 2005). 
Contrasting results have been reported also about how A3AR activation might influence 
neuronal activity in rat brain. Dunwiddie and coworkers (1997) demonstrated that in the 
CA1 region of the rat hippocampus A3AR has no direct effect on synaptically evoked 
excitatory responses, while it induced heterologous desensitization of A1AR, thus 
limiting adenosine-mediated cerebroprotection. Others suggested that A3AR activation 
in cortical neurons mediated a depression of synaptic transmission by inhibiting 
glutamate release additionally to and independently from the A1 receptors, thus 
providing neuroprotection ([Brand et al., 2001], [Lewerenz et al., 2003] and [Lopes et 
al., 2003b]). It was also found that activation of A3AR by endogenous adenosine 
inhibited synaptic transmission during hypoxia in rat cortical neurons (Hentschel et al., 
2003), and the inhibitory function of A3AR activation was in agreement with an in vivo 
report showing that A3AR has depressant effects on locomotor activity in behavioral 
tests (Jacobson et al., 1993). However, on the other hand it has been observed that Cl-
IB-MECA facilitates epileptiform discharges in the CA3 area of immature rat 
hippocampal slices, suggesting that activation of A3AR following a rise in endogenous 
adenosine facilitates excitation, thus limiting the known inhibitory and neuroprotective 
effects of adenosine in immature brain (Laudadio & Psarropoulou, 2004). Genetic 
suppression of A3AR enhanced some aspects of motor function, suppressed pain 
processing at supraspinal levels and showed an increase in neurodegeneration in 
response to repeated episodes of hypoxia, suggesting the possible use of A3 agonists in 
the treatment of ischemic and degenerative conditions of the CNS (Fedorova et al., 
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2003). Different evidences suggest that a part of neuroprotection induced by A3AR 
derives from its modulation of the brain immune system (Haskó et al., 2005). It has 
been reported that functional A3AR are expressed in mouse microglia cells, where their 
activation is responsible for a biphasic effect on ERK1/2 phosphorylation (Hammarberg 
et al., 2003) and in murine astrocytes where A3AR stimulation induces the release of the 
neuroprotective chemokine CCL2 (Wittendorp et al., 2004). Moreover, in 
lipopolysaccharide (LPS)-treated BV2 microglial cells A3AR activation suppresses 
tumor necrosis factor-α (TNF-α) production by inhibiting PI3K/Akt and nuclear factor-
κB (NF-κB) activation, suggesting that selective ligands of this receptor may be of 
therapeutic potential for the modulation and possible treatment of brain inflammation 
(Lee et al., 2006a). Even though for some aspects the role of A3AR in the CNS seems 
less confusing now than in the past, there are many aspects yet that need clarification 
before a role of A3 agonists in therapy can be envisioned. 
Cardioprotection versus cardiotoxicity 
 
To date several pieces of evidence support the conclusion that activation of A3AR is 
crucial for cardioprotection during and following ischemia–reperfusion and it has been 
suggested that a consistent part of the cardioprotective effects exerted by adenosine, once 
largely attributed to the A1 receptor, may now be in part ascribed to A3AR activation 
(Headrick & Peart, 2005). Even though there is a low expression of A3AR in myocardial 
tissue, a number of studies have demonstrated that acute treatment with agonists induced 
protective “anti-ischemic” effects (Auchampach et al., 1997a; Tracey et al., 1997;  
Thourani et al., 1999a; Ge et al., 2006 and Xu et al., 2006). The molecular mechanism of 
A3AR cardioprotection has been attributed to regulation of mitochondrial (mito) KATP 
channels (Thourani et al., 1999b; Shneyvays et al., 2004 and Peart and Headrick, 2007). 
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In addition Shneyvays et al. (2005) demonstrated that in cultured rat myocytes Cl-IB-
MECA delayed the dissipation of the mitochondrial membrane potential (∆ψ) and 
decreased the elevated intracellular calcium concentrations induced by hypoxia. These 
effects prevented irreversible cardiomyocyte damage and confirmed previous results 
showing that A3AR activation protected cardiomyocytes treated with doxorubicin via 
inhibition of calcium overload and prevented cardiomyocyte death during incubation in 
high extracellular calcium concentrations (Shneyvays et al., 2001 and Shneyvays et al., 
2004). As for the timing of cardioprotection, some studies have indicated that protection 
occurred post-ischemia, through inhibition of neutrophil-induced reperfusion injury or 
inhibition of myocyte apoptotic cell death (Jordan et al., 1999 and Maddock et al., 2002), 
while others found that preischemic A3AR activation was effective and necessary for 
cardioprotection (Thourani et al., 1999a). Auchampach et al. demonstrated that A3 
agonism was able to trigger an anti-infarct response with either pre- or postischemic 
treatment (Auchampach et al., 2003). Moreover, it has been reported that A3AR 
activation is able to mimic or induce myocardial preconditioning, meaning that transient 
stimulation of the A3AR before induction of ischemia leads to both an early and a 
delayed protection (Peart & Headrick, 2007). The first condition has been shown to 
require mito KATP channel activation through PKC, 1,2-diacylglycerol (DAG), PLD and 
RhoA, but also reduction of caspase 3 and increase of cell survival through 
MEK/ERK1/2 and PI3K pathways (Parsons et al., 2000; Sato et al., 2000; Lee et al., 
2001; Nakai et al., 2001; Germack and Dickenson, 2004 and Germack and Dickenson, 
2005). In addition it has been reported that resveratrol preconditions the heart through 
A3AR signaling that triggers a survival effect mediated by the Akt-Bcl2-Bad signaling 
pathway and also by another survival signal mediated via Akt-dependent and 
independent CREB phosphorylation (Das et al., 2005a and Das et al., 2005b). In terms of 
delayed preconditioning some authors reported a role for mito KATP channels but not for 
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nitric oxide synthase (iNOS), while other acquired evidence of NF-κB and iNOS 
involvement (Takano et al., 2001 and Zhao and Kukreja, 2002). Pharmacological 
preconditioning (early and late) obtained after A3AR activation is clinically important, 
but cardioprotection is even more relevant when it occurs at reperfusion (Auchampach et 
al., 2003 and Xu et al., 2006). This situation, called post-conditioning, has been 
demonstrated for IB-MECA through inhibition of the mitochondrial permeability 
transition pore (mPTP) opening via PI3K/Akt inactivation of glycogen synthase kinase 
(GSK-3β; Kin et al., 2005 and Park et al., 2006). The cardioprotective effects of A3 
receptors were also detected in A3AR-overexpressing mice where after in vivo regional 
ischemia and reperfusion, infarct size was lower than in wild-type mice (Black et al., 
2002). In these animals A3AR overexpression decreased basal heart rate and 
contractility, preserved ischemic ATP and decreased postischemic dysfunction (Cross et 
al., 2002). On the other hand, the results obtained with mice carrying higher transgene 
copy numbers suggested that basal signaling was increased when the A3AR was 
expressed at higher levels, leading to the development of a dilated cardiomyopathy. 
Paradoxically, in contrast with pharmacological evidence of A3-induced cardioprotection 
the first studies carried out in mice in which the A3AR was genetically disrupted 
demonstrated an improvement of cardiac function as revealed from a smaller myocardial 
infarct size (Guo et al., 2001). Cerniway and colleagues (2001) reported similar 
beneficial effects in A3KO mice, which they initially ascribed to the absence of a 
proinflammatory action of A3AR mediated through mast cell degranulation. 
Subsequently, it was suggested that this effect might be due to compensatory changes 
that developed in the KO mice due to the chronic absence of A3AR (Harrison et al., 
2002). In this respect, recent evidence obtained by using pharmacological agents and 
genetic methods suggests that Cl-IB-MECA protects against myocardial 
ischemia/reperfusion injury in mice via A3AR activation. These conclusions were 
 26
supported by experiments with a selective A3 antagonist and through evaluation of the 
A3 agonist effects on A3KO mice. Interestingly, in this paper by using congenic 
(C57BL/6) A3KO mice, deletion of the A3 gene itself had no effect on ischemic 
tolerance, suggesting that previous opposite results from the same group (Guo et al., 
2001) were probably explained by differences in the genetic background of the mice 
rather than specific deletion of the A3 gene. Additional studies using wild-type mice 
treated with compound 48/80, a condensation product of p-methoxyphenetyl 
methylamine with formaldehyde, to deplete mast cell contents excluded the possibility 
that Cl-IB-MECA was cardioprotective by releasing mediators from mast cells (Ge et al., 
2006) and supported the idea that therapeutic strategies focusing on A3AR subtype may 
represent a novel and useful approach for protection of the ischemic myocardium. The 
A3-mediated cardioprotection remains a mystery if one thinks of its cellular location. 
Literature data reported that myocardial A3AR expression in the mouse is very low and 
below the detection limits of radioligand binding or northern blot techniques (Black et 
al., 2002). It is also surprising that mice overexpressing the A3AR reveal only 
12 fmol/mg of protein and that animals with 66 fmol/mg of protein present negative 
effects like dilated cardiomyopathy, meaning that the level of A3AR is very critical for 
heart function. Therefore, on the one hand it is possible to hypothesize that given the 
strong cardioprotective effects and the low cardiac expression, this receptor must be very 
efficiently coupled to protective intracellular signaling pathways. On the another hand, it 
is also conceivable that cardioprotection might derive at least in part from activation of 
A3AR expressed in other cells (Jacobson & Gao, 2006; Fig. 2). 
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    Anti-inflammatory versus proinflammatory effects 
The interest in the elucidation of A3AR involvement in inflammation is attested by the 
large amount of experimental work carried out in cells of the immune system and in a 
variety of inflammatory conditions. However, as in the SNC or in the cardiovascular 
system the A3AR subtype appears to have a complex or “enigmatic” role, as both 
proinflammatory and antiinflammatory effects have been demonstrated. One of the first 
evidence for a role of A3AR in increasing inflammation derived by studies in mast cells 
where it was found that its activation was responsible for release of allergic mediators 
(Ramkumar et al., 1993 and Fozard et al., 1996). In addition, it has been reported that 
A3AR mRNA was higher in lung tissue of patients with airway inflammation and that 
A3AR activation mediates rapid inflammatory cell influx into the lungs of sensitized 
guinea pigs (Walker et al., 1997 and Spruntulis and Broadley, 2001). It has been 
reported that A3AR activation in RBL-2H3 mast cells inhibits apoptosis and may have a 
profound effect on survival of inflammatory cells expressing A3AR in inflamed tissues, 
thus contributing to inflammatory cell expansion (Gao et al., 2001). Moreover, antigen-
dependent degranulation of bone marrow-derived mast cells was found to be mediated 
by A3AR (Reeves et al., 1997), and the ability of Cl-IB-MECA to potentiate antigen-
dependent mast cells degranulation was lost by using mice lacking A3AR, suggesting a 
role for antagonists as antiasthmatic agents (Salvatore et al., 2000). The involvement of 
A3AR in mast cells degranulation has been further confirmed in murine lung mast cells 
where it was dependent from Ca++ elevations through Gi and PI3K coupling (Zhong et 
al., 2003). However, in contrast with these findings it has been demonstrated that in the 
rat parenchymal strip, where contraction in response to adenosine is mast cell mediated, 
the receptor involved shows similarities to the A3AR but Cl-IB-MECA is a high affinity 
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antagonist and MRS 1523 and MRS 1191 are inactive at concentrations that 
substantially exceed their affinities for the rat A3AR by adding further twist to A3AR 
pharmacology (Wolber & Fozard, 2005). Moreover, it has been shown that human and 
canine mast cells degranulation was mediated by A2BAR instead of A3AR (Feoktistov 
and Biaggioni, 1995; Auchampach et al., 1997b and Ryzhov et al., 2004). This 
discrepancy reflects the low human and rat overall coidentity at the amino acid level of 
A3AR and questions the role of the A3AR as a target for asthma therapy. Nevertheless 
the high expression of A3AR in other cells involved in allergic diseases and asthma still 
gives reason to suggest a role for antagonists in the treatment of these pathologies. In 
particular transcript levels for the A3 subtype are elevated in the lungs of asthma and 
COPD patients, where expression is localized to eosinophilic infiltrates. Interestingly, 
similar findings were made in the lungs of adenosine deaminase deficient (ADA−/−) 
mice that exhibited adenosine-mediated lung disease. Treatment of ADA−/− mice with 
MRS 1523, a selective A3 antagonist, prevented airway eosinophilia and mucus 
production. Similar results were obtained in the lungs of ADA/A3 double KO mice, 
suggesting that A3 signaling plays an important role in regulating chronic lung disease 
and that A3 antagonism may provide a mechanism for reducing eosinophilia (Young et 
al., 2004). These results are in contrast with experiments performed in human 
eosinophils ex vivo, where chemotaxis such as degranulation and superoxide anion 
production were reduced by A3AR activation (Ezeamuzie & Philips, 1999). This 
discrepancy may be due to differences in mouse and human eosinophils or to 
differences attributed to the ex vivo nature of the chemotaxis experiments performed. 
Additional studies of A3-mediated effects on mouse eosinophils ex vivo confirmed the 
results observed in human cells, suggesting that diminished airway eosinophilia seen in 
the lungs of ADA−/− mice following disruption of A3AR is not a cell autonomous effect 
of eosinophils. Rather A3 disruption in ADA−/− mice is likely to affect the expression 
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and activity of key regulatory molecules from other cells that present A3AR and that 
affect eosinophil migration (Young et al., 2004). For example A3AR are expressed on 
murine mast cells, airway macrophages and epithelial cells, all of which might affect 
eosinophil migration. However, levels of key regulatory cytokines such as IL-5 and IL-
13, or chemokines including eotaxin I, thymus- and activation-regulated chemokine 
(TARC) and monocyte chemotactic protein-3 (MCP3) were not affected by A3 removal 
in ADA−/− mice, pointing perhaps to the involvement of A3 subtype in the regulation of 
other key modulators of eosinophil migration, such as cell adhesion molecules, 
extracellular matrix elements and proteases (Young et al., 2004). The molecular 
mechanisms by which A3 signaling may affect eosinophil chemotaxis are not known, 
but may involve the regulation of intracellular calcium (Khono et al., 1996a). In 
addition to influencing chemotaxis, A3 engagement might also affect eosinophils 
survival. It has been reported that A3 subtype can protect rat mast cells from apoptosis 
by a pathway involving PI3K and phosphorylation of PKB. In the same way, activation 
of A3AR on eosinophils may promote their survival at sites of inflammation. However, 
the functional role of the A3 subtype in the pathogenesis of asthma remains 
controversial and differences in the pharmacology of A3 subtype from different species 
render it difficult to understand whether an A3AR agonist or antagonist could be needed 
to improve the treatment of asthma. At this regard, a recent paper by Rimmer and 
coworkers reports the effect of a novel A2A agonist/A3AR antagonist in the treatment of 
allergic rhinitis through a randomized, double-blind, placebo-controlled study (Rimmer 
et al., 2007). Unfortunately, this ligand appears to have limited clinical benefit in both 
the early- and late-phase response to intranasal allergen challenge, even though it 
reduced the release of some mediators after allergene challenge. However, as correctly 
pointed out by the authors, the study presented a number of shortcomings. As an 
example the dose of the drug was limited by the narrow therapeutic index, due to side 
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effects like tachycardia, raising the possibility that higher doses of new compounds with 
fewer side effects might be more efficacious. Alternatively, it is possible that future 
studies targeting a different receptor, perhaps the A2B, or using dual antagonists versus 
A3/A2BAR will be more successful (Press et al., 2005). 
Discrepancy between anti- and proinflammatory effects induced by A3AR have been 
observed also in other cell types. For example, A3AR are expressed in human 
neutrophils where they are involved together with A2A in the reduction of superoxide 
anion generation (Bouma et al., 1997 and Gessi et al., 2002). However, recently an 
elegant study by Chen et al. reported that neutrophils rapidly hydrolyze released ATP to 
adenosine that then acts via A3-subtype adenosine receptors, which are recruited to the 
leading edge, to promote cell migration (Chen et al., 2006a and Linden, 2006). 
In addition to a role of A3AR in increasing inflammation, evidence that A3AR decrease 
inflammation have also been reported in literature. As an example, it has been shown 
that A3AR suppress TNF-α release induced by endotoxin CD14 receptor signal 
transduction pathway from human monocytes and murine J774.1 macrophages (Le 
Vraux et al., 1993 and McWhinney et al., 1996). Moreover, in a macrophage model the 
A3AR was the prominent subtype implicated in the inhibition of LPS-induced TNF-α 
production (Sajjadi et al., 1996). This effect was associated with changes in stimulation 
of the activator protein-1 (AP-1) transcription factor, whereas it was independent of 
MAPK and NF-κB, PKA, PKC and PLC. This was not confirmed in BV2 microglial 
cells where A3-mediated inhibition of LPS-induced TNF-α expression was associated 
with the inhibition of LPS-induced activation of PI3K/Akt and NF-κB pathway (Lee et 
al., 2006a). The inhibitory effect induced by A3AR on TNF-α production was also 
assessed in A3KO mice where the A3 agonist was unable to reduce TNF-α levels in 
contrast with its effect in wild-type animals (Salvatore et al., 2000). Recently, it has 
 31
been reported that in mouse RAW 264.7 cells the A3 subtype inhibits LPS-stimulated 
TNF-α release by reducing calcium-dependent activation of NF-κB and ERK 1/2 
(Martin et al., 2006) while in peritoneal macrophages, isolated from A3KO mice, the 
ability of IB-MECA to inhibit TNF-α release was not altered in comparison to wild-type 
mice (Kreckler et al., 2006). In this study, the inhibitory effect was exerted through the 
activation of A2A and A2B agonists as recently demonstrated also in human monocytes 
(Zhang et al., 2005 and Haskó et al., 2007). The discrepancy observed among these 
papers might not depend on species differences, being in both cases mouse cells, but by 
other factors including the source of the cells, and/or the inflammatory stimulus used. 
However in spite of these contrasting results, one of the best potential therapeutic 
applications of the regulatory role of A3 activation on TNF-α release has been found in 
the treatment of arthritis. A3AR agonists exert significant antirheumatic effects in 
different autoimmune arthritis models by suppression of TNF-α production (Baharav et 
al., 2005). The molecular mechanism involved in the inhibitory effect of IB-MECA on 
adjuvant-induced arthritis included receptor down-regulation and deregulation of the 
PI3K–NF-κB signaling pathway (Fishman et al., 2006 and Madi et al., 2007). Previous 
studies also demonstrated that A3AR activation inhibited macrophage inflammatory 
protein (MIP)-1α, that is a C-C chemokine with potent inflammatory effects, in a model 
of collagen-induced arthritis, providing the first proof of concept of the adenosine 
agonists utility in the treatment of arthritis (Szabò et al., 1998). 
In agreement with an antiinflammatory role for the A3AR, it has been recently 
demonstrated that A3AR activation decreases mortality and renal and hepatic injury in 
murine septic peritonitis (Lee et al., 2006b). Higher levels of endogenous TNF-α were 
observed in A3KO mice after sepsis induction, in comparison to wild-type animals and 
IB-MECA significantly reduced mortality in mice lacking the A1 or A2A but not the 
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A3AR, demonstrating specificity of the A3 agonist in activating A3 subtype and 
mediating protection against sepsis-induced mortality (Lee et al., 2006b). A similar 
mortality reduction associated with a decrease of IL-12 and interferon-γ (IFN-γ) 
production induced by A3AR activation was previously observed by Haskó et al. (1998) 
in endotoxemic mice. In addition other investigators reported reduced inflammation and 
increased survival following A3 activation in 2 murine models of colitis (Mabley et al., 
2003). Furthermore, a protective role for A3AR in lung injury following in vivo 
reperfusion has been recently reported (Matot et al., 2006). In contrast, it has been 
demonstrated that A3AR activation exacerbates renal dysfunction and mice lacking 
A3AR have been found to have better renal function following renal ischemia 
reperfusion injury (Lee and Emala, 2000 and Lee et al., 2003). A3 receptors have been 
found to be up-regulated in ocular ischemic diseases and in conditions associated with 
oxidative stress. Their activation lead to the regulation of chloride channels in 
nonpigmented ciliary epithelial cells, suggesting that A3 agonists would increase 
aqueous humor secretion and thereby intraocular pressure in vivo, while antagonists 
may represent a specific approach for treating ocular hypertension (Mitchell et al., 1999; 
Okamura et al., 2004 and Schlotzer-Schrehardt et al., 2005). 
 
Antitumor versus tumorigen effects 
A very interesting area of potential application of A3 ligands concerns cancer therapies. 
The possibility that A3 adenosine receptor plays a role in the development of cancer has 
aroused considerable interest in recent years (Fishman et al., 2002 and Merighi et al., 
2003 and Gessi et al., 2008). The A3 subtype has been described in the regulation of the 
cell cycle and both pro- and antiapoptotic effects have been reported depending on the 
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level of receptor activation (Jacobson, 1998; Yao et al., 1997; Gao et al., 2001; Merighi 
et al., 2005a; Nakamura et al., 2006 and Gessi et al., 2007). Starting from the 
observation that muscle tissues are resistant to tumor metastases, it was reported that 
one of the active components of muscle cell conditioned medium was adenosine, that 
exerted a differential effect on tumor and normal cell growth (Fishman et al., 1998); this 
inhibition was removed when the A3AR was blocked, while it was mimicked following 
A3AR agonist stimulation. The mechanism was found to involve inhibition of 
telomerase activity and arrest in the G0/G1 phase of the cell cycle, leading to a cytostatic 
effect (Fishman et al., 2000). In addition, it was demonstrated that A3AR inhibited 
tumor growth by regulation of the WNT pathway (Fishman et al., 2004). The WNT 
pathway, active during embryogenesis and tumorigenesis, mediates cell cycle 
progression and cell proliferation. A key modulator of this pathway is represented by 
GSK-3β that is crucial for β-catenin phosphorylation. β-Catenin induces the 
transcription of genes fundamental for cell cycle progression such as c-myc and cyclin 
D1. Upon exposure of tumor cells to the A3 agonist, a decrease in the protein expression 
level of A3AR and the downstream effectors PKA and PKB was observed. 
Consequently, the GSK-3β protein level increased, resulting in the destabilization of β-
catenin and the subsequent suppression of cyclin D1 and c-myc expression (Fig. 4). IB-
MECA treatment also induced down-modulation of the expression of NF-κB, known to 
regulate the transcription of cyclin D1 and c-Myc (Fishman et al., 2003 and Fishman et 
al., 2004). Moreover A3AR agonist treatment induced inhibition of tumor growth both 
in vitro and in vivo, gave a synergistic effect in combination with chemotherapy and 
exhibited a myelostimulatory effect by inducing G-CSF production by mononuclear 
cells, thus leading to the development of A3 agonists in clinical trials for colon 
carcinoma (Jacobson & Gao, 2006). Other authors found inhibition of cell proliferation 
or induction of apoptosis by treating cells with the A3 agonist, but the effects generally 
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were observed only at micromolar doses and the involvement of the A3 subtype was 
questioned (Wen and Knowles, 2003; Panjehpour and Karami-Tehrani, 2004; Merighi 
et al., 2005a and Nakamura et al., 2006). In this respect several observations may be 
underlined: (i) it has been demonstrated that Cl-IB-MECA at micromolar doses inhibits 
cell proliferation and this effect is reduced by blocking the receptor, supporting a role 
for the A3 subtype (Merighi et al., 2005a); (ii) it has been previously reported that IB-
MECA, at micromolar doses in breast cancer cells, inhibits cell proliferation through 
interaction with receptors different from the adenosine subtypes such as estrogen 
receptor α (Lu et al., 2003); (iii) at micromolar doses Cl-IB-MECA loses its selectivity 
for A3 receptors and the complicating presence of interaction with other adenosine 
subtypes might be involved in the final response; (iv) the difference between the effects 
induced by low and high doses of Cl-IB-MECA could be attributed to the receptor 
desensitization of A3 receptors that has been demonstrated by other authors in various 
cell systems (Trincavelli et al., 2002a). Conversely, it has been demonstrated that A3AR 
in retinal ganglion cells was obligatory for life (Zhang et al., 2006), and it has been 
recently observed in colon cancer cells that after treatment with ADA, Cl-IB-MECA 
increased cell proliferation through the activation of A3 subtype and involvement of 
ERK1/2 (Gessi et al., 2007). It is important to underline that all these experiments have 
been performed in normoxic conditions. From another point of view, hypoxia that is 
typical of solid tumors (Vaupel et al., 1989), creates conditions that, on one hand, are 
conducive to the accumulation of extracellular adenosine and, on the other hand, 
stabilize hypoxia-inducible factors, such as HIF-1α ([Blay et al., 1997], [Semenza, 
2000], [Hockel and Vaupel, 2001], [Linden, 2001], [Minchenko et al., 2002], 
[Fredholm, 2003] and [Sitkovsky et al., 2004]). HIF-1, the most important factor 
involved in the cellular response to hypoxia, is up-regulated across a broad range of 
cancer types and is involved in key aspects of tumor biology, such as angiogenesis, 
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invasion and altered energy metabolism (Semenza, 2003). HIF-1 is a heterodimer 
composed of an inducibly expressed HIF-1α subunit and a constitutively expressed 
HIF-1β subunit (Epstein et al., 2001). HIF-1α and HIF-1β mRNAs are constantly 
expressed under normoxic and hypoxic conditions (Wiener et al., 1996). The unique 
feature of HIF-1 is the regulation of HIF-1α expression: it increases as the cellular O2 
concentration is decreased (Semenza, 2000 and Minchenko et al., 2002). During 
normoxia, HIF-1α is rapidly degraded by the ubiquitin proteasome system, whereas 
exposure to hypoxic conditions prevents its degradation (Minchenko et al., 2002). A 
growing body of evidence indicates that HIF-1 contributes to tumor progression and 
metastasis (Welsh and Powis, 2003 and Hopfl et al., 2004). Immunohistochemical 
analyses have shown that HIF-1α is present in higher levels in human tumors than in 
normal tissues (Zhong et al., 1999). Interestingly, it has been demonstrated that A3AR 
are also overexpressed in cancer tissues in comparison to normal mucosa (Gessi et al., 
2004a). Furthermore, attention has been paid to responses to chronic hypoxia that 
involve adenosine-induced changes in the transcription regulator HIF-1 expression. In 
particular, the correlation between adenosine receptor stimulation and HIF-1α 
expression modulation in hypoxia has been investigated. Adenosine increases HIF-1α 
protein expression in response to hypoxia in human melanoma, glioblastoma and colon 
cancer cells (Merighi et al., 2005b; Merighi et al., 2006 and Merighi et al., 2007b). 
These results indicate that the cell surface A3AR transduces extracellular hypoxic 
signals into the cell interior. Increased HIF-1α protein synthesis through the activation 
of the Akt or MAPKinase pathways is a common theme accounting for the up-
regulation. To evaluate how A3AR accumulates HIF-1α in hypoxia, the signaling 
pathway generated by A3AR stimulation has been investigated and it was found that 
MAPKinase activity is required for the HIF-1α expression increase induced by A3AR 
activation (Fig.3). Furthermore, as HIF-1α plays a key role in inducing angiogenesis, we 
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have also studied the role of adenosine in mediating the production of VEGF in tumor 
cells. Activation of the A3AR in glioblastoma and colon cancer cells stimulates VEGF 
expression (Merighi et al., 2006 and Merighi et al., 2007b), whereas this receptor 
subtype promotes VEGF downregulation in PC12 pheochromocytoma cells (Olah & 
Roudabush, 2000). It has been proposed that the effect of VEGF on new capillary 
formations is facilitated by the concomitant stimulation of A2B and A3 receptors that 
induce the expression of angiopoietin-2 (Feoktistov et al., 2003). Indeed, the activation 
of A3 receptors results in increased expression of angiopoietin-2 in mast and melanoma 
cells (Feoktistov et al., 2003 and Merighi et al., 2005b). Although adenosine may 
contribute rather little to the increase in VEGF induced by hypoxia, it may contribute as 
much as 50% to angiogenesis (Adair, 2005). This could mean that adenosine acts also 
independently of VEGF, something that is not unlikely given the involvement of 
multiple cell types and multiple angiogenetic factors. Recent studies indicate that 
pharmacological inhibition of HIF-1α and particularly of HIF-regulated genes, that are 
important for cancer cell survival, may be more advantageous than therapeutic 
approaches based on HIF-gene inactivation. In this regard, A3AR antagonists are able to 
block HIF-1α, angiopoietin-2 and VEGF protein expression accumulation in hypoxia, 
indicating a new approach for the treatment of cancer, based on the cooperation between 
hypoxic and adenosine signals. 
Figure.3 
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Immunosuppressive versus immunostimulating effects 
The ability of immune cells to fight tumor cells is fundamental for successful host 
defense against cancer. Adenosine, whose concentration increases within hypoxic 
regions of solid tumors, may interfere with the recognition of tumor cells by cytolytic 
effector cells of the immune system (Blay et al., 1997 and Merighi et al., 2003). 
Adoptive immunotherapy with lymphokine-activated killer (LAK) cells has shown 
some promise in the treatment of certain cancers that are unresponsive to conventional 
treatment approaches. However, colon adenocarcinomas tend to respond poorly to LAK 
therapy, possibly as a result of tumor-induced immunosuppression. It has been 
demonstrated that colon adenocarcinoma cells inhibited anti-CD3-activated killer cell 
induction through the production of a tumor-associated soluble factor that was distinct 
from transforming growth factor beta or prostaglandins (Hoskin et al., 1994a). 
Therefore, adenosine was indicated as a possible inhibitor of killer T-cell activation in 
the microenvironment of solid tumours (Hoskin et al., 1994b and Hoskin et al., 1994c). 
Indeed, evaluating the adhesion of murine spleen-derived anti-CD3-activated killer 
(AK) lymphocytes to syngeneic MCA-38 colon adenocarcinoma cells it was found that 
adenosine reduced adhesion by up to 60% (MacKenzie et al., 1994). The inhibitory 
effect of adenosine was exerted on AK cells and not on the MCA-38 targets and the 
agonist potency profile indicated that the A3 receptor subtype might be responsible for 
the inhibition of adhesion. The authors suggested that this mechanism of 
immunosuppression, secondary to tissue hypoxia, may be important in the resistance of 
colorectal and other solid cancers to immunotherapy. In addition the same authors 
demonstrated that adenosine plays a strong inhibitory effect on the induction of mouse 
cytotoxic T cells (Hoskin et al., 2002). Diminished tumoricidal activity correlated with 
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reduced expression of mRNAs coding for granzyme B, perforin, Fas ligand and TNF-
related apoptosis-inducing ligand (TRAIL). IL-2 and IFN-γ synthesis by AK-T cells 
was also inhibited by adenosine. The inhibitory effect of adenosine on AK-T cell 
proliferation was also blocked by an A3 receptor antagonist suggesting that adenosine 
acts through A3 receptors to prevent AK-T cell induction. Tumor-associated adenosine 
may act through the same mechanism to impair the development of tumor-reactive T 
cells in cancer patients. Therefore, the suppression of T-killer cell function suggests that 
adenosine may act as a local immunosuppressant within the microenvironment of solid 
tumors. Subsequently, it was reported that adenosine partially inhibits the interaction of 
T lymphocytes with tumor cells by blocking the function of integrin α4β7 that is the 
major cell adhesion molecule involved in the adhesion of T cells to syngeneic MCA-38 
adenocarcinoma cells (MacKenzie et al., 2002). The effect of adenosine has been 
investigated on the expression of costimulatory molecules by T cells in resting and 
activated conditions. One of the most important costimulatory molecules present on the 
T cells surface are CD2 and CD28 acting in concert to achieve optimal costimulation of 
T lymphocytes during interaction with antigen presenting cells. It has been 
demonstrated that adenosine interfered with activation-induced expression of the 
costimulatory molecules CD2 and CD28 in a way IL-2 dependent but not involving the 
accumulation of intracellular cAMP, possibly by activating the A3 subtype (Butler et al., 
2003). However, recent data obtained from studies using adenosine receptor KO mice 
examined the capability of adenosine and its analogues to inhibit the ability of LAK to 
defeat tumor cells. This work demonstrated that adenosine and adenosine A2A ligands 
suppress the cytotoxicity of LAK cells in parallel with their ability to increase cAMP 
levels. These effects were produced by interfering with both perforin-mediated and Fas 
ligand-mediated killing pathways. Studies with LAK cells generated from A1 and A3AR 
KO mice indicated the lack of any involvement of these adenosine subtypes in the 
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inhibitory effect exerted by adenosine, whereas LAK cells obtained from A2AR KO 
mice were resistant to the inhibitory effect of the nucleoside. Only very high 
concentrations of the non selective agonists 5-N-ethylcarboxamide adenosine (NECA) 
or 2-chloroadenosine (CADO) produced mild inhibition of LAK cytotoxicity that were 
possibly induced through A2B activation, suggesting the predominant role of the A2A 
subtype in inhibition of LAK cell toxicity (Raskovalova et al., 2005). Therefore, the 
authors indicate the use of A2A antagonists to increase the efficacy of immunotherapy 
(Fredholm, 2007). In contrast to the immunosuppressive role of adenosine in the 
environment of solid tumors, it has been reported that A3AR activation stimulates the 
proliferation of bone marrow cells in vitro. This effect was induced through the 
adenosine-mediated G-CSF production by peripheral blood mononuclear cells (PBMC). 
In vitro studies were also confirmed by in vivo experiments, which revealed an increase 
in leukocyte and neutrophil numbers, when adenosine was administered before 
chemotherapy (Bar-Yehuda et al., 2002). The molecular mechanism at the basis of G-
CSF production included the upregulation of PI3K, PKB/Akt and NF-κB. In addition, it 
has been observed that Cl-IB-MECA potentiates the activity of NK cells in naïve and 
tumor bearing mice through the induction of IL-12 production; this effect was 
dependent on inhibition of cAMP levels and PKA expression. IL-12 is a potent 
stimulant of NK cells and is a cytotoxic factor that exerts a potent anti-tumor effect in 
vivo. It induces IFN-γ production by activated T and NK cells and augments cytotoxic 
activity of these cells via perforin, Fas and Trail-dependent mechanisms. Therefore, 
A3AR activation enhances NK cell activity and probably NK cell-mediated destruction 
of tumor cells (Harish et al., 2003). This antitumor effect played in immune cells is in 
line with other findings of the same group demonstrating a direct inhibitory action of A3 
receptor activation on tumor cell growth (Fishman et al., 2003) 
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GLIOBLASTOMA TUMORS 
Introduction and Histological Classification 
 
The most common primary brain tumor is the glioma. Histologically, gliomas can resemble 
astrocytes, oligodendrocytes, or ependymal cells; thus, on the basis of their morphologic appearance 
they are classified as astrocytomas, oligodendrogliomas, or ependymomas, respectively (1–5). 
Astrocytomas express glial fibrillary acidic protein, an intermediate filament found in astrocytes 
that is routinely used as an aid in classifying a glioma as an astrocytoma. 
Primary brain tumors account for 1.4% of all cancers and 2.4% of all cancer deaths in the United 
States, and  approximately 20,500 newly diagnosed cases and 12,500 deaths are attributed to 
primary malignant brain tumors each year. The risk factors for the development of a glioma are not 
clear, but occupational exposure to organic solvents or pesticides appears to be a predisposing 
factor.  It has also been suggested that cytomegalovirus (CMV) infection may play a role in the 
etiology or progression of some gliomas, based on detection of CMV RNA in glioblastoma (GBM) 
tumors (7). There are two peak incidences of gliomas, one in the age group of 0 to 8 years (8) and 
the second in the age group of 50 to 70 years (5), and there is a slight male predominance (9). 
The symptoms of patients presenting with a glioma depend on the anatomical site of the glioma in 
the brain and can include headaches; nausea or vomiting; changes in speech, vision, hearing, or 
balance; mood and personality alterations; seizures or convulsions; and memory deficits .The time 
frame of the onset of symptoms depends in part on the grade of the glioma; with GBM tumors the 
onset of symptoms is typically rapid. Surgical biopsy is necessary to determine whether the tumor is 
a primary brain tumor and to diagnose the tumor type and grade. 
Glioma tumors are histologically separated into Grades I through IV according to the World Health 
Organization (WHO) criteria. Grade I tumors typically have a good prognosis and more frequently 
occur in children (5, 8), and Grade II tumors are characterized on histologic examination by 
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hypercellularity: These Grade II tumors have a 5–8-year median survival. Grade III astrocytoma 
tumors (anaplastic astrocytoma tumors) are characterized on histologic examination according to 
hypercellularity, as well as nuclear atypia and mitotic figures (see Figure 4). Anaplastic astrocytoma 
has a 3-year median survival (10–14). Grade IV gliomas, also known as GBMs, are characterized 
on histologic examination according to hypercellularity, nuclear atypia, mitotic figures, and 
evidence of angiogenesis and/or necrosis (see Figure 5). The median survival for patients with 
GBM tumors is 12–18 months, and older patients (>60 years of age) typically have a survival that 
is somewhat shorter than the median. 
Oligodendroglioma tumors are histologically separated into Grades II and III according to the WHO 
criteria. The Grade II tumors exhibit hypercellularity and bland nuclei on histologic examination 
(see Figure 6), and the Grade III tumors (anaplastic oligodendrogliomas) exhibit the additional 
histologic features of prominent mitotic figures and evidence of angiogenesis. 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                   Figure 4 
Anaplastic astrocytoma (World Health Organization Grade III). A mitotic 
                    figure is shown in the bottom center of the photomicrograph, and tumor nuclei 
are pleomorphic. Both are typical of an anaplastic astrocytoma. 
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                                                                 Figure 5 
                    Glioblastoma tumor (World Health Organization Grade IV). Endothelial cell 
                    proliferation (angiogenesis) is shown in the center of this photomicrograph. 
 
 
 
 
 
                        
 
                                                                  Figure 6 
                   Oligodendroglioma (World Health Organization Grade II). The cleared 
              cytoplasm and bland monomorphic nuclei typical of an oligodendroglioma are 
                                            shown in this photomicrograph. 
  
Major Genetic Alteration 
The ongoing characterization of the genetic alterations in glioma tumor cells is revealing 
considerable variability among tumors of the same type and grade. This heterogeneity may 
contribute to the current limitations in predicting patient survival on the basis of histologic analysis 
of glioma type and grade alone and suggests that classification of certain types and grades of 
gliomas according to their genetic phenotype will lead to a more accurate prediction of survival and 
response to therapy. Grade I tumors, which are frequently benign, typically do not progress to 
Grade II, III, or IV tumors, and their genetic alterations are different from those found in the Grade 
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II–IV tumors; thus, they are not discussed herein. Oligodendroglioma (WHO Grade II) and 
anaplastic oligodendroglioma tumors (WHO Grade III) frequently exhibit loss of heterozygosity 
(LOH) on chromosomes 1p and 19q (observed in 40%–90% of biopsies, depending on the study) 
.This is the most common genetic alteration found in oligodendroglioma tumors and predicts a 
favorable response to certain chemotherapeutic agents, a favorable response to radiation therapy, 
and longer survival even after recurrence. Glioma biopsy tissue can be routinely tested for LOH on 
chromosome 1p and 19q by fluorescence in situ hybridization (FISH) or by Southern blotting in the 
pathology laboratory. It is not yet known which genes at the 1p and 19q loci are involved in the 
promotion of growth of the oligodendroglioma tumors nor how the loss of these genes contributes 
to a more favorable therapeutic response and a more favorable prognosis; however, at least one of 
these genes may be involved in the initiation of oligodendroglial tumorigenesis .Another common 
genetic alteration in oligodendroglial tumors is downregulation of the tumor suppressor and lipid 
phosphatase PTEN gene. Downregulation of this gene has been found in 50% of these tumors, and 
this downregulation appears to be a consequence of methylation of the promoter region. 
 Amplification of platelet-derived growth factor receptor alpha (PDGFRα) occurs in approximately 
7% of oligodendroglial tumors. Astrocytoma tumors (WHO Grade II) frequently (3%–33%) exhibit 
amplification of the PDGFRα and/or PDGFRβ genes and of the genes encoding their ligands, 
PDGF-A and -B or  C and -D. The amplification of the PDGFRα gene may result from 
amplification of chromosome 4q12. These genetic alterations probably play an important role in 
gliomagenesis, given that retroviral expression of PDGF-B in neural progenitor cells can initiate 
gliomagenesis in newborn mice and in adult rats. 
In astrocytomas that do not express high levels of PDGF-A and -B, expression of PDGF-C and -D 
may be increased and is thought to substitute for the protumorigenic role of PDGF-B. Loss of p53 is 
also a common genetic event in astrocytoma tumors (WHO Grade II). In the more malignant form 
of astrocytoma, anaplastic astrocytoma (WHO Grade III), loss of the gene that encodes the cell-
cycle progression regulator Rb, which occurs as a consequence of the deletion of chromosome 
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13q13, is detected in approximately 30% of tumors. Downregulation or mutation of the tumor-
suppressor gene p16INK4A/CDKN2A occurs in approximately 50% of these tumors. The 
downregulation can occur as a result of either hypermethylation of the promoter region or loss of 
the chromosome 9p region. The p16INK4A and ARF genes are encoded by a single genetic locus 
known as INK4a/ARF, which is located at chromosome 9p21 and encodes the precursor of 
p16INK4A and ARF. Approximately 50% of anaplastic astrocytoma tumors have a mutation of the 
p53 gene. In addition, the gene encoding the endogenous p53 inhibitor, MDM2 (on chromosome 
12q), is amplified in 13% to 43% of these tumors. As a consequence of the alterations in the 
Rb1/CDK4/p16INK4A and p53/p14ARF genes, signals that negatively regulate the cell cycle are 
interrupted, resulting in deregulated cell proliferation. Loss of chromosome 22q and gain of 
chromosome 7q are also found in approximately 20% of anaplastic astrocytoma tumor samples, but 
the identity of the gene(s) or loci that contribute to anaplastic astrocytoma tumorigenesis or 
progression is not yet known. GBMtumors (WHO Grade IV) can be subdivided into primary and 
secondary tumors on the basis of the patient’s age at presentation and the genetic alterations in the 
tumor. Primary GBM tumors present de novo in older patients (typically >60 years of age) without 
a preexisting lower-grade glioma, and they account for approximately 90% of all GBM tumors. 
SecondaryGBMtumors arise from a preexisting Grade II or III astrocytoma or from a mixed glioma 
(oligoastrocytoma). In primary GBM tumors, amplification and/or mutation of the gene encoding 
epidermal growth factor receptor (EGFR), found on chromosome7, occurs in up to 60% of tumors. 
The most common mutation is a gain-of-function mutation due to an in-frame deletion of exons 2–
7; this mutation results in the constitutive activation of EGFR, which can promote glioma cell 
proliferation and invasion. Deletion of the lipid phosphatase gene, PTEN, due to LOH of 
chromosome 10q or mutation, is also a common genetic occurrence in the primary GBM tumors; 
this deletion results in increased AKT/mTOR activity, which promotes cell survival, proliferation, 
and invasion. Both amplification of the EGFR gene and LOH of the PTEN gene can be readily 
detected by FISH or Southern blotting in the pathology laboratory. Several other potential 
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tumorsuppressor gene candidates on chromosome 10q, such as DMBT1 (deleted in malignant brain 
tumors 1) and the Myc antagonist Mxi1, have been proposed. Also, the MDM2 gene (an inhibitor of 
p53 on chromosome 12q) is amplified in approximately 10% to 15% of GBM tumor samples. 
Hypermethylation of the promoter of the gene encoding the DNA-repair enzyme, MGMT, occurs in 
both primary GBM(36%) and secondary GBM (75%) tumors and indicates a better response to 
temozolomide therapy. Heterogeneity in glioma tumors is also found within individual tumors. For 
example, certain areas of a glioma tumor may experience hypoxic conditions. Hypoxia results in the 
activation of proangiogenic genes and a focally increased angiogenic response. Also, breakdown of 
the blood-brain barrier can occur focally within a glioma tumor, resulting in leakage of serum-
derived extracellular matrix proteins into certain areas of the tumor. Focal expression of serum-
derived extracellular matrix proteins can alter integrin signaling and the motility of the glioma cells.  
 
Molecular Mechanisms Contributing to the Proliferative and Invasive 
Phenotype 
 
Like other malignant tumors, glioma tumors proliferate rapidly. This highly proliferative phenotype 
is due to the loss of multiple cell cycle inhibitors as well as to increased signaling from multiple 
growth factor receptors that act through downstream effectors to exert positive effects on the 
regulation of the cell cycle. The growth factor receptors that initiate a proliferative signal in these 
tumors include EGFR and PDGFR. Frequently, expression of both the ligand and the receptor is 
increased in glioma tumors, suggesting that there exists an autocrine or paracrine loop that amplifies 
signaling. Importantly, the EGFR and the PDGFR growth factor receptors cooperate or coordinate 
with cell adhesion receptors, such as integrins and Eph kinases, resulting in an amplification of the 
growth factor receptor signal. Growth factor receptors and cell-adhesion receptors typically rapidly 
activate focal adhesion kinase (FAK), a cytoplasmic nonreceptor tyrosine kinase. FAK is a major 
positive regulator of cell-cycle progression and acts by increasing extracellular signal–regulated 
kinase (ERK) activity and cyclin D1 transcription, as well as by inhibiting expression of p27Kip1. 
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Gliomas are invasive tumors. For the malignant gliomas, the invasive phenotype is a highly 
characteristic feature; others have referred to this phenotype as a signature feature. As with the 
proliferative phenotype, growth factor receptor signaling plays a major role in promoting the 
invasive phenotype in cooperation with, or in coordination with, cell-adhesion receptors and 
proteases. Multiple growth factor receptors have been shown to promote glioma cell migration and 
invasion, including c-Met, EGFR, and PDGFR. Typically, there is increased expression of both the 
growth factor receptor and ligand in the tumor, again suggesting that an autocrine or paracrine loop 
that promotes signaling is in place. Members of several different families of celladhesion receptors, 
including members of the integrin family, the Eph/Ephrin family, and the CD44 family, have been 
shown to promote glioma cell migration and invasion. In some instances, expression of cell-
adhesion receptors, such as integrins alpha v beta 3 and alpha v beta 5, is increased in malignant 
glioma tumors. The integrin receptors provide the interaction with the cytoskeleton of the cell that 
generates the traction that enables the cell to pull itself forward. Regarding the Eph/Ephrin family, 
current data indicate that the Ephrin-B3 ligand and the Eph-B3 receptor promote glioma cell  
invasion. Cell-surface receptors from different classes or families probably cooperate or coordinate 
signaling events in a context dependent manner that is also regulated temporally. Signaling 
molecules in the glioma cells act downstream of the cell-surface growth factor receptor and cell-
adhesion receptor to amplify and propagate the proinvasion signal. These signaling molecules 
include cytoplasmic tyrosine kinases, adaptor molecules, and cytoskeletal proteins. For example, 
both the tyrosine kinase FAK (72, 86, 98, 99) and another member of this family, Pyk2, can 
promote glioma cell migration and invasion in a contextdependent manner. The Src family tyrosine 
kinases also are necessary for glioma cell invasion. Adaptor molecules from the Crk-associated 
substrate (CAS) family, such as HEF1 and p130CAS, promote glioma invasion, and members of the 
Crk family of adaptor molecules act downstream of HEF1 or CAS proteins in this process. Two 
signaling molecules that regulate glioma cell survival and proliferation, phosphatidylinositol-3-
kinase (PI3K) and PTEN, also regulate glioma cell migration and invasion. PI3K positively 
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regulates glioma cell migration and invasion (105). PTEN appears to negatively regulate these 
processes; thus, the loss of PTEN function in malignant gliomas can promote glioma cell invasion. 
Glioma cell invasion most likely requires protease degradation of the extracellular matrix. Several 
families of proteases, including the serine proteases, cathepsins, matrix metalloproteinases (MMPs), 
and the ADAMTS family of metalloproteases, have been shown to play a role in glioma cell 
migration and invasion. Protease activity can be regulated by multiple factors in a tumor. One 
important aspect of this regulation is the localization of protease function in specific regions of the 
tumor cell membrane. An example of this process is the localization of the serine protease, 
urokinase. Urokinase expression is increased inGBM tumors in vivo, and downregulation either of 
urokinase or of its receptor (the urokinase receptor) inhibits glioma cell invasion. The binding of 
urokinase to its receptor localizes this protease to specific areas of the cell membrane and promotes 
its activity in these areas because the binding of urokinase to its receptor is necessary for optimal 
protease activity. Also, the receptor colocalizes with specific integrin receptors on the cell 
membrane, further specifying the membrane region that exhibits protease activity. A second 
example is the binding of MMP-2 to integrin alpha v beta 3 on the cell surface, which both localizes 
and enhances the activity of this protease. Thus, proteases act in concert with cell-surface receptors 
and downstream signaling molecules to promote glioma cell invasion. 
 
 
 
Treatmen of Glioblastoma tumor 
Treating glioblastoma is a complex process, requiring a variety of techniques and procedures. The 
initial treatment often includes steroid medications to reduce swelling and inflammation of brain 
tissue, as well as anticonvulsant medications to prevent and control seizures if you have 
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experienced them. If fluid has built up in the brain, a physician may insert a shunt–a long, thin tube 
that draws excess fluid from the brain. Common treatments to remove or reduce the size of 
glioblastoma include a combination of surgery, radiation therapy, and chemotherapy. For all 
operable tumors, surgery followed by radiation therapy and chemotherapy is recommended to 
improve patients’ survival. Surgeons work to remove as much of the glioblastoma as possible while 
trying to minimize damage to healthy tissue. Some tumors can be removed completely while others 
only partially or not at all. To gain access to the tumor, surgeons may cut bone from the skull in a 
procedure called craniotomy and replace the bone after the procedure. Some surgeons use a 
highpowered microscope (microsurgery) or computer programs that create 3-D maps of the tumor’s 
location; these maps help surgeons to remove tumors with minimal damage to healthy tissue  and 
can reduce your pain and recovery time. In some situations, ultrasonic waves can be used to break 
apart the tumor, with the fragments removed by suction, in a procedure called ultrasonicaspiration. 
Sometimes, to prevent cancer from coming back, surgeons place chemotherapy coated wafers in the 
space where a tumor has been removed. Radiation therapy–pinpointed high-energy beams–can 
shrink tumors or destroy cancer cells remaining after surgery. This treatment is also an option if 
surgery is not possible. Radiation therapists sometimes use 3-D maps similar to what surgeons use 
to deliver radiation in the exact size and shape of the tumor. 
A common treatment regimen involves seven weeks of targeted radiation treatment combined with 
a chemotherapy drug called temozolomide (Temodar®), which makes the tumor more sensitive to 
the radiation therapy. Because of the difficulty of treating glioblastoma, you should consider 
enrolling in a clinical trial testing new treatments. These treatments are highly experimental in 
nature but may be an option, especially for advanced cancers. Some trials may involve biologic 
therapy, which uses the natural defenses of the immune system to fight cancer.  
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AIM OF THE THESIS 
Adenosine is an endogenous and ubiquitous nucleoside that exerts many biological functions 
through interaction with 4 distinct subtypes of G protein-coupled receptors divided into A1, A2A, 
A2B, and A3. This nucleoside plays an important role in modulating inflammation and tumorigenesis. 
In the past  most of the anti-inflammatory effects of this nucleoside were thought to be due to the 
activation of the A2A subtype, however more recently, the involvement of the A3 subtype has been 
also considered relevant for the outcome of inflammation.  
Cells involved in inflammation are important substrates on which adenosine plays multiple 
physiological functions. In the chapter 1 we will summarize the status of the art on the role of the A3 
receptor in different types of immune cells including neutrophils, eosinophils, lymphocytes, 
monocytes, macrophages and dendritic cells.  
Several studies in literature and obtained in our laboratory have shown that adenosine exert 
important modulatory function in the growth of tumors, giving an essential role in this to the A3 
receptor. In particular local invasive growth is one of the key features of primary brain tumors. 
Glioma is the most common primary adult brain tumor with poor prognosis because of the 
aggressive invasion of the surrounding normal brain. Although our understanding of glioma 
oncogenesis has steadily improved, the molecular mechanisms that mediate glioma invasion are still 
poorly understood. The degradation of extracellular matrix (ECM) which exerts biochemical and 
mechanical barriers to cell movement has been shown to be an important biological process in tumor 
invasion and metastasis [1]. The metalloproteinases (MMPs) are a family of enzymes able to 
degrade and remodel the extracellular matrix. They are involved in many physiological and 
pathological processes, including inflammation and tumor growth. In particular, the degradation of 
extracellular matrix (ECM), which exerts a mechanical and biochemical barrier to cell movement, 
was demonstrated to be an important biological process in the invasion and the tumor metastatic 
process.  In particular, it was demonstrated that MMP9 facilitates in vitro invasion of glioblastoma 
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cells and the up-regulation of this metalloproteinase is associated with the progression of malignant 
glioma in vivo.  
Therefore the aim of chapter 2  will be to evaluate the involvement of adenosine on the regulation of 
metalloproteinases and in particular of MMP9 in U87MG glioblastoma cells.  
In chapter 2, we showed that adenosine is able to increase both MMP9 mRNA and protein levels 
through the activation of the A3 adenosine receptor using real time RT-PCR and Western blotting. 
We noted that the A3 receptor stimulation led to increased levels of MMP9 protein in cellular 
extracts of U87MG cells, through phoshorylation of ERK1/2, JNK, Akt/PKB and the transcription 
factor AP-1. 
The A3 receptor activation also led an increase in extracellular levels of MMP9 in the supernatants 
of glioblastoma cells as evaluated by ELISA and gelatine zymography assays. Finally, as for the 
physiological relevance of the A3 receptor-mediated stimulation of MMP9 we found that the A3 
agonist was responsible for an increase of the invasive ability of U87MG cells. 
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A3 adenosine receptor regulation of cells of the immune system and modulation 
of inflammation 
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Abstract 
The interest in the elucidation of A3 adenosine receptor involvement in inflammation is evident from 
the large amount of experimental work carried out in peripheral blood cells of the immune system 
and in a variety of inflammatory conditions. Following a detailed analysis of the literature the A3 
adenosine receptor subtype appears to play a complex role as both pro and anti-inflammatory effects 
have been demonstrated depending not only on the cell types investigated but also on the model of 
inflammation used and the species considered (Gessi et al., 2008). This chapter will discuss 
developments in our understanding of the role of adenosine A3 receptor activation in the function of 
the different types of cells of the immune system including neutrophils, eosinophils, lymphocytes, 
monocytes, macrophages and dendritic cells. 
 
A3 adenosine receptor effects on neutrophil function 
Neutrophils represent a larger percentage of circulating leukocytes than any other cell type. They are 
the first white blood cells to arrive at an injured or infected site. Neutrophils arise in the bone 
marrow and then must traverse the vasculature to arrive at the sites of injury. They leave the 
circulation at the level of the postcapillary venules following specific interaction with endothelium. 
Once in the extravascular space, neutrophils follow a gradient set up by chemoattractants, such as 
activated complement components, cytokines, lipids or bacterial products by means of specific cell 
surface receptors. Although the primary role of the neutrophil is to rid the body of injurious 
organisms and clean up the debris after tissue injury, the extracellular release of any of the contents 
of the phagolysosome or the generation of toxic oxygen metabolites into the extracellular space can 
lead to destruction of normal, uninjured cells surrounding the infected site. It is the destruction of the 
surrounding tissue by overactive neutrophils  that adds so greatly to tissue destruction in the setting 
of reperfusion injury. Adenosine, acting through its cell surface receptors, is a potent regulator of 
neutrophil function. 
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The first report implicating a role for A3 receptors in human neutrophils came in 1997 following 
investigations into the effect of adenosine and its more selective analogues on neutrophil 
degranulation in human whole blood (Bouma et al., 1997). Adenosine inhibited concentration-
dependently the LPS- and TNF-alpha-induced release of the azurophilic granule proteins with an 
IC50 in the µmolar range. The inhibitory effects of adenosine were partially blocked by the A2 
receptor antagonist 3,7-dimethyl-1-propargylxanthine, the A1/A2 antagonist 8(p-
sulfophenyl)theophyline, and the A1/A3 antagonist xanthine amine congener, but not by the A1 
antagonist 1,3-dipropyl-8-cyclopentylxanthine. The highly selective A3 agonist N6-(3-iodobenzyl)-
adenosine-5'-N-methyluronamide and the nonselective agonist 2-chloroadenosine reduced 
degranulation more potently than the A1 agonist N6-cyclopentyladenosine. The inhibitory effects of 
N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide and 2-chloroadenosine were strongly reversed 
by xanthine amine congener, but were not affected by 8(p-sulfophenyl)theophyline. These data 
suggest that adenosine acted via A2 as well as A3 receptors to inhibit neutrophil degranulation. 
However, activation of A3 receptors in canine neutrophils did not attenuate superoxide anion 
production but reduced platelet-activating factor-stimulated neutrophil adherence to coronary 
endothelium suggesting that it might be a novel target for treatment of myocardial ischemia and 
reperfusion (Jordan et al., 1999). 
Subsequent binding and functional studies showed that human neutrophils expressed A3 receptors 
which were coupled to the inhibition of adenylyl cyclase and calcium signalling (Gessi et al., 2002). 
However in the case of calcium the high micromolar doses of the A3 agonist 2-chloro-N6-(3-
iodobenzyl)adenosine-5'-N-methylcarboxamide (Cl-IB-MECA) and the A3 antagonist 5-N-(4-
methoxyphenyl-carbamoyl)amino-8-propyl-2(2furyl)-pyrazolo-[4,3e]-1,2,4-triazolo[1,5-c] 
pyrimidine (MRE 3008F20) needed to stimulate or block Ca2+ mobilization respectively, were not 
completely consistent with the involvement of an A3 receptor. Similar effects of Cl-IB-MECA in 
mobilizing Ca2+ have been found in several cell systems a finding that is difficult to reconcile with 
the high affinity of this selective A3 agonist in binding and cAMP inhibition assays (Kohno et al., 
 74
1996a,b; Jacobson, 1998; Reeves et al., 2000; Reshkin et al., 2000; Shneyvays et al., 2000; Gessi et 
al., 2001; Suh et al., 2001; Merighi et al., 2001). The reason why high, nonselective doses of Cl-IB-
MECA are needed to stimulate Ca2+ mobilization remains unknown. A contribution of other 
mechanisms other than A3 receptor stimulation cannot be excluded. Importantly, for the first time it 
was suggested that both A3 and A2A receptors contribute  to the inhibition of oxidative burst, an 
indication of anti-inflammatory activity (Gessi et al., 2002). Using this readout, alterations of A3 
adenosine receptors in human neutrophils exposed to low frequency, low energy pulsing 
electromagnetic fields (PEMFs) has been reported. There is considerable interest in the use of 
PEMFs in clinical practice since the date correlate well with inflammatory conditions. Saturation 
experiments after treatment with PEMFs revealed that the A3 receptor density in human neutrophils 
was increased. Consistent with this in functional assays Cl-IB-MECA and N6-(3-
iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) were able to inhibit cyclic AMP 
accumulation and their potencies were increased after exposure to PEMFs. These results indicated 
that in human neutrophils treated with PEMFs there are significant alterations in the A3 adenosine 
receptor density and functionality (Varani et al., 2003). The upregulation cannot be ascribed to the 
synthesis of new receptors since the duration of PEMF treatment was too short. The upregulation of 
A3 adenosine receptors is most likely due to a translocation of this receptor subtype to the membrane 
surface. It is of interest that PEMFs treatment also modified the binding parameters of the A2A 
adenosine receptors but not those of α2, β2 adrenergic and µ, k opioid receptors suggesting a 
relationship between adenosine receptor-mediated anti-inflammatory effects and PEMF exposure 
(Varani et al., 2002). 
An up-regulation of the A3 adenosine receptor has also been observed in neutrophils obtained from 
patients with colorectal cancer in comparison with healthy subjects. This overexpression was found 
to reflect at peripheral level the same up-regulation found in the tumoral tissue from the colon in 
comparison to healthy mucosa, suggesting that peripheral A3 adenosine receptors in neutrophils 
might represent potential marker for revealing colorectal cancer (Gessi et al., 2004a). It was also 
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found that in a small cohort of subjects A3 receptor expression of circulating blood cells normalizes 
after surgical treatment, consistent with the negative results of follow-up evaluation with 
carcinoembryonic antigen (CEA), computed tomography scan, and colonoscopy. Hence, the 
improved health of patients after surgical resection seems to be associated with restoration of a 
normal adenosinergic system, at least in terms of A3 receptor expression. These findings might be 
used for clinical applications. In particular, examination of neutrophil A3 expression (for example, in 
addition to CEA determination) could play a role in the screening of high-risk individuals or in the 
follow-up of patients after surgical resection. 
Recently Chen et al., reported that migrating human neutrophils secrete ATP at the leading edge, 
which signals via P2Y2 receptors to amplify chemoattractant signals (Chen et al., 2006a). 
Neutrophils rapidly hydrolyze released ATP to adenosine which then acts via A3 receptors, which 
are recruited to the leading edge, to promote cell migration. In resting cells, A3 receptors appear to 
be located primarily in intracellular compartments associated with granules (Chen et al., 2006a). 
Upon cell stimulation with chemoattractant, A3 receptors are rapidly mobilized at the leading edge to 
promote chemotaxis. Thus, ATP release and autocrine feedback through P2Y2 and A3 receptors 
provides signal amplification and controls gradient sensing and migration of neutrophils. 
Interestingly, chemotaxis of neutrophils obtained from A3 receptor knockout (KO) animals is 
inhibited.  In contrast, A2A receptors are uniformly distributed across the cell surface and cell 
polarization does not seem to change this distribution pattern (Chen et al., 2006a). This suggests that 
the inhibitory A2A receptors may function to globally suppress pseudopod formation across the 
entire cell surface of neutrophils, except at the leading edge, where A3 adenosine receptor counteract 
the suppressive action of A2A receptors (Chen et al., 2006a; Linden, 2006; Junger, 2008). However, 
these findings were questioned recently by Hoeven et al. (2008) who demonstrated that A3 
adenosine receptor activation is responsible for inhibition of superoxide production and chemotaxis 
of mouse bone marrow neutrophils, suggesting that the A3 receptor may contribute to the anti-
inflammatory actions of adenosine. Although there are many differences between this study and the 
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earlier work, including the species difference (mouse vs human), the pharmacological agents used to 
stimulate the A3 adenosine receptor (CP-532,903 versus IB-MECA), the methods used to 
isolate/culture murine neutrophils, the stimulation protocols (including the time and duration of 
pretreatment of cells with agonists), and the state of cell priming, a definite explanation for the 
differences in results obtained in these studies remains unclear.  
Consistent with a pro-inflammatory role of A3 adenosine receptors in human neutrophils it has been 
demonstrated that A3 receptors together with P2Y subtypes mediate neutrophil elastase release 
induced by hypertonic saline (Chen et al., 2006b). Hypertonic saline holds promise as a novel 
resuscitation fluid for the treatment of trauma patients because it inhibits polymorphonuclear 
neutrophil activation and thereby prevents host tissue damage and associated post-trauma 
complications. However, under certain conditions of cell activation, hypertonic saline can increase 
neutrophil degranulation, which could exacerbate tissue damage in trauma victim (Chen et al., 
2006b). The cellular mechanism by which hypertonic saline increases degranulation involves 
elastase release and ERK and p38 MAPK activation when hypertonic saline is added after 
submaximal activation of neutrophils with formyl peptide (fMLP) or phorbol ester (PMA). Agonists 
of P2 nucleotide and A3 adenosine receptors mimicked these enhancing effects of hypertonic saline, 
whereas antagonists of A3 receptors or removal of extracellular ATP with apyrase diminished the 
response to hypertonic saline suggesting that hypertonic saline upregulates degranulation via ATP 
release and positive feedback through P2 and A3 receptors. It has been hypothesized that these 
feedback mechanisms can serve as potential pharmacological targets to fine-tune the clinical 
effectiveness of hypertonic saline resuscitation (Chen et al., 2006b). In this context, it has been 
shown that A3 receptor activation may diminish the efficacy of hypertonic saline in a mouse model 
of acute lung injury after sepsis (Inoue et al., 2008a). Acute lung injury in wild-type mice treated 
with hypertonic saline 60 min after sepsis induction, through cecal ligation and puncture (CLP), was 
significantly greater than in wild-type mice pretreated for 5 and 15 min with hypertonic saline. 
Parallel experiments aimed at evaluating the expression of A3 receptors in human neutrophils treated 
 77
with hypertonic saline either 10 min before or after stimulation with formyl methionylleucyl-
phenylalanine (fMLP) reveal that in the first condition A3 receptor expression was reduced whilst in 
the second one it was markedly increased. These findings show that the opposing effects of 
hypertonic saline in vivo correlate with differences in the cell surface expression of A3 receptors, 
suggesting that the enhancing effects of hypertonic saline are a result of increased A3 receptor 
expression of stimulated neutrophils. The aggravating effect of delayed hypertonic saline treatment 
was absent in A3 receptor knockout (KO) mice. Similarly, mortality in wild-type mice with delayed 
hypertonic saline treatment was significantly higher than in animals treated with hypertonic saline 
before CLP. Mortality in A3 receptor KO mice remained at only 50% regardless of timing of 
hypertonic saline administration. These findings suggest that A3 antagonists could improve the 
efficacy of hypertonic saline resuscitation by reducing side effects in patients whose 
polymorphonuclear neutrophils are activated before hypertonic saline treatment. The role of A3 and 
P2Y2 receptors in neutrophil sequestration in the lungs in a mouse model of sepsis has also been 
demonstrated (Inoue et al., 2008b). Sepsis was induced by CLP using wild type mice, homozygous 
A3 receptor KO mice, and P2Y2 receptor KO mice. The data suggest that A3 and P2Y2 receptors are 
involved in the influx of neutrophils into the lungs after sepsis. Neutrophil sequestration in the lungs 
reached a maximum 2 h after CLP and remained significantly higher in wild type mice compared 
with A3 KO and P2Y2 KO mice. Survival after 24 h was significantly lower in WT mice than in A3 
KO or P2Y2 KO mice. Thus, pharmaceutical approaches that target these receptors might be useful 
to control acute lung tissue injury in sepsis.  
It has been recognized that the inflammatory response to infection depends on the coordinated 
interaction of the adenine nucleotides, ATP, ADP and adenosine released by damaged tissue 
(Linden, 2006). Therefore the contribution of A3 receptors expressed in neutrophils, must be in 
concert with the other purinergic receptors to allow neutrophil adhesion, extravasation and 
chemotaxis. Neutrophils express predominantly A2A and A3 receptors which have opposite effects 
on these cells. In this chapter we have described how neutrophils following gradients of ATP and 
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adenosine initiate and increase the speed of chemotaxis via P2Y and A3 receptors, respectively and 
that the A2A may amplify gradient signals by inhibiting chemotaxis at membrane region distant from 
the leading edge where the A3 receptor predominates and increases chemotaxis. This seems possible 
given that the affinity of adenosine for the A2A receptor is several orders of magnitude higher than 
its affinity for the A3 receptors. Thus, differences in external adenosine concentrations in the 
environment surrounding migrating neutrophils may contribute to the regulation of chemotaxis 
(Chen et al., 2006a). A coordinated activity of A2A and A3 receptors has also been found with respect 
to degranulation and superoxide anion production in human neutrophils where both receptors 
cooperate to fine-tune the inflammatory response (Bouma et al., 1997; Gessi et al., 2002). However, 
it is important that the inhibitory effect exerted by A2A and A2B receptors on chemotaxis and 
adhesion to endothelial cells, respectively can overcome the stimulatory effect exerted by A3 when 
excessive influx of neutrophils damages host tissues (Zhang et al., 2006). After activation of A3 
receptors opposite effects on inflammation have been reported depending essentially on the response 
considered, the experimental conditions and the species used. It is relevant to underline that by 
comparing the studies performed in human neutrophils both anti and proinflammatory effects have 
been demonstrated (Figure 1). Therefore caution should be used before proposing A3 agonists as anti 
or proinflammatory agents until a more definite role of this receptor has been defined. 
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Fig. 1-Effects of A3 adenosine receptors in neutrophils. 
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A3 adenosine receptor effects on eosinophil function 
Eosinophils are one of the immune system components responsible for combating infection. Along 
with mast cells, they also control mechanisms associated with allergy and asthma. Eosinophils 
develop and mature in the bone marrow. They differentiate from myeloid precursor cells in response 
to the cytokines interleukin 3 (IL-3), interleukin 5 (IL-5), and granulocyte macrophage colony-
stimulating factor (GM-CSF). Eosinophils produce and store many secondary granule proteins prior 
to their exit from the bone marrow. After maturation, eosinophils circulate in blood and migrate to 
inflammatory sites in tissues, in response to chemokines such as CCL11 (eotaxin-1), CCL24 
(eotaxin-2), CCL5 (RANTES), and leukotriene B4 (LTB4). At these infectious sites, eosinophils are 
activated by Type 2 cytokines released from a specific subset of helper T cells (Th2); thus IL-5, GM-
CSF, and IL-3 are important for eosinophil activation as well as maturation. Following activation, 
eosinophils release the contents of small granules within the cellular cytoplasm, which contain many 
chemical mediators, such as histamine and proteins such as eosinophil peroxidase, RNase, DNases, 
lipase, plasminogen, and major basic protein that are toxic to both parasite and host tissues (Gleich 
and Adolphson, 1986). 
A3 receptors are present on human eosinophils and couple to signalling pathways that lead to cell 
activation ( Kohno et al., 1996a; Reeves et al., 2000).  Despite this it has not proven easy to 
demonstrate the functional consequences of activation of these sites (Reeves et al., 2000).  
Nevertheless, the chronic inflammation in asthma is characterised by extensive infiltration of the 
airways by activated eosinophils  (Holgate, 1999; Pearlman, 1999) and it remains possible that the 
elevated adenosine concentrations associated with asthma  would contribute to eosinophil activation 
through stimulation of A3 receptors.  In addition, it has been speculated that activation of A3 
receptors may protect eosinophils from apoptosis (Gao et al., 2001).  Thus, blockade of A3 receptors 
may reduce the numbers of eosinophils and their activation thereby reducing the pro-inflammatory 
burden in the lung.  Consistent with this, following 6 weeks treatment of mild asthmatics with 
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theophylline there was a significant reduction in the number of activated eosinophils beneath the 
epithelial basement membrane (Sullivan et al., 1994).  Significantly, the average blood levels in this 
study (37 µM) were within the range of the affinity of theophylline for the human A3 receptor.  
Moreover, it has been reported that activation of A3 receptors mediates inhibition of eosinophil 
chemotaxis (Knight et al., 1997).  The authors argue that since adenosine levels are highest at the 
site of inflammation, A3 receptor activation would be pro-inflammatory by inhibiting eosinophil 
migration away from the sites of inflammation.  Clearly,  however, inhibition of chemotaxis could 
be pro- or anti-inflammatory. In line with a pro-inflammatory role, a high expression of A3 receptor 
transcripts has been found in eosinophilic infiltrates of the lungs of patients with asthma and chronic 
obstructive pulmonary disease (COPD) (Walker et al., 1997). Interestingly, similar findings were 
seen in the lungs of adenosine deaminase deficient (ADA-/-) mice that showed adenosine-mediated 
lung disease. Treatment of ADA-/- mice with MRS 1523, a selective A3 receptor antagonist, 
prevented airway eosinophilia and mucus production. Similar results were obtained in the lungs of 
ADA/ A3 receptor double KO mice, suggesting that A3 receptor signalling plays an important role in 
regulating chronic lung disease and that A3 receptor antagonism may be useful for reducing 
eosinophilia (Young et al., 2004). However these results contrast with those from experiments 
performed in human eosinophils ex vivo, where chemotaxis, degranulation and superoxide anion 
production were reduced by A3 receptor activation (Knight et al., 1997; Walker et al., 1997; 
Ezeamuzie and Philips, 1999). This discrepancy was later attributed to the ex vivo nature of the 
chemotaxis experiments and implied that diminished airway eosinophilia seen in the lungs of ADA-/- 
mice following disruption of A3 receptor is not a direct effect on the eosinophils but be due to the 
modulation of key regulatory molecules from other cells that express A3 receptors and that affect 
eosinophil migration (Young et al., 2004). For example A3 receptors are expressed on murine mast 
cells, airway macrophages and epithelial cells, all of which might affect eosinophil migration. 
However levels of key regulatory cytokines such as IL-5 and IL-13, or chemokines including 
eotaxin I, thymus- and activation-regulated chemokine (TARC) and monocyte chemotactic protein-3 
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(MCP3) were not affected by A3 receptor deletion in ADA-/- mice, pointing perhaps to the 
involvement of A3 receptor in the regulation of other key modulators of eosinophil migration such as 
cell adhesion molecules, extracellular matrix elements and proteases (Young et al., 2004). In 
contrast to a pro-inflammatory role of the A3 subtype implied by the work of Young and colleagues 
cited above, the involvement of the A3 adenosine receptor in a bleomycin model of pulmonary 
inflammation and fibrosis seems to indicate an anti-inflammatory effect (Morschl et al., 2008). 
Analysis of A3 adenosine receptor KO mice revealed enhanced pulmonary inflammation including 
an increase in eosinophils and a selective up-regulation of eosinophil related chemokines and 
cytokines in the lungs of A3 adenosine receptor KO mice exposed to bleomycin. This increase in 
eosinophil numbers was accompanied by a decrease in the eosinophil peroxidase activity in lavage 
fluid from A3 adenosine receptor KO mice exposed to bleomycin, an observation suggesting the A3 
adenosine receptor is necessary for eosinophil degranulation in this model. Together these results 
suggest that the A3 adenosine receptor mediates anti-inflammatory functions in the bleomycin 
model, and is also involved in regulating the production of mediators that can impact fibrosis 
(Morschl et al., 2008). The effects obtained in human eosinophils after A3 receptor activation 
including inhibition of chemotaxis, degranulation, oxidative burst and the effects obtained from in 
vivo models of lung disease such as eosinophilia and mucus production are summarized in Figure 2. 
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Fig. 2-Effects of A3 adenosine receptors in eosinophils 
Given the important species differences in the location and functional response to A3 receptors, only 
the effects obtained in human are in bold. 
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A3 adenosine receptor effects on lymphocyte function 
The ability of immune cells to fight tumor cells is fundamental for successful host defence 
against cancer. Adenosine, whose concentration increases within hypoxic regions of solid 
tumors, may interfere with the recognition of tumor cells by cytolytic effector cells of the 
immune system (Blay et al., 1997; Merighi et al., 2003). Adoptive immunotherapy with 
lymphokine-activated killer (LAK) cells has shown some promise in the treatment of certain 
cancers that are unresponsive to conventional treatment approaches. However, colon 
adenocarcinomas tend to respond poorly to LAK therapy, possibly as a result of tumor-induced 
immunosuppression. It has been demonstrated that colon adenocarcinoma cells inhibited anti-
CD3-activated killer cell induction through the production of a tumor-associated soluble factor 
that was distinct from transforming growth factor beta or prostaglandins (Hoskin et al., 1994a). 
As a result, adenosine was suggested as a possible inhibitor of killer T-cell activation in the 
microenvironment of solid tumours (Hoskin et al., 1994b; Hoskin et al., 1994c). Indeed, 
evaluating the adhesion of murine spleen-derived anti-CD3-activated killer (AK) lymphocytes 
to syngeneic MCA-38 colon adenocarcinoma cells it was found that adenosine reduced 
adhesion by up to 60% (MacKenzie et al., 1994). The inhibitory effect of adenosine was exerted 
on AK cells and not on the MCA-38 targets and the agonist potency profile indicated that the 
A3 receptor subtype might be responsible for the inhibition of adhesion. The authors suggested 
that this mechanism of immunosuppression, secondary to tissue hypoxia, may be important in 
the resistance of colorectal and other solid cancers to immunotherapy. In addition the same 
authors demonstrated that adenosine plays a strong inhibitory effect on the induction of mouse 
cytotoxic T cells (Hoskin et al., 2002). Diminished tumoricidal activity correlated with reduced 
expression of mRNAs coding for granzyme B, perforin, Fas ligand and TNF-related apoptosis-
inducing ligand (TRAIL). Interleukin-2 (IL-2) and interferon-γ (IFN-γ) synthesis by AK-T cells 
was also inhibited by adenosine. The inhibitory effect of adenosine on AK-T cell proliferation 
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was also blocked by an A3 receptor antagonist suggesting that adenosine acts through A3 
receptors to prevent AK-T cell induction. Tumor-associated adenosine may act through the 
same mechanism to impair the development of tumor-reactive T cells in cancer patients. 
Therefore the suppression of T-killer cell function suggests that adenosine may act as a local 
immunosuppressant within the microenvironment of solid tumors. Subsequently it was reported 
that adenosine partially inhibits the interaction of T lymphocytes with tumor cells by blocking 
the function of integrin α4β7 which is the major cell adhesion molecule involved in the 
adhesion of T cells to syngeneic MCA-38 adenocarcinoma cells (MacKenzie et al., 2002). The 
effect of adenosine has been investigated on the expression of costimulatory molecules by T 
cells in resting and activated conditions. The most important costimulatory molecules present 
on the T cells surface are CD2 and CD28 acting in concert to achieve optimal costimulation of 
T lymphocytes during interaction with antigen presenting cells. It has also been demonstrated 
that adenosine interferes with activation-induced expression of the co-stimulatory molecules 
CD2 and CD28 by an IL-2 dependent mechanism but not involving the accumulation of 
intracellular cAMP and possibly by activating the A3 subtype (Butler et al., 2003). Subsequently 
the inhibitory effect mediated by adenosine on the ability of LAK cells to kill tumor cells was 
attributed essentially to the cAMP-elevating A2A receptor whilst no evidence of the involvement 
of cAMP inhibitory A1 or A3 subtypes in the regulation of the cytotoxic activity of LAK cells 
was found (Raskovalova et al., 2005). Indeed, it has been suggested that hypoxic cancerous 
tissues may be protected by the same hypoxia→adenosine→A2A receptor pathway that was 
recently shown to be critical and nonredundant in preventing excessive damage of normal 
tissues by overactive immune cells in vivo (Ohta et al., 2001). 
In contrast to the immunosuppressive role of adenosine in the environment of solid tumors, it 
has been reported that A3 receptor activation stimulates the proliferation of murine bone marrow 
cells in vitro. This effect was induced through the G-CSF production by human peripheral 
blood mononuclear cells (PBMC) mediated by adenosine. The finding was confirmed in in vivo 
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experiments, which revealed an increase in leukocyte and neutrophil numbers when adenosine 
was administered before chemotherapy (Fishman et al., 2000). The molecular mechanisms 
underlying G-CSF production included the upregulation of  the PI3K, PKB/Akt and NF-kB 
pathways (Bar-Yehuda et al., 2002). In addition, it has been observed that Cl-IB-MECA 
increases the activity of NK cells in naïve and tumor bearing mice through the induction of IL-
12; this effect was dependent on inhibition of cAMP levels and PKA expression. IL-12 is a 
potent stimulant of NK cells and is a cytotoxic factor that exerts a potent anti-tumor effect in 
vivo. It induces IFN-γ production by activated T and NK cells and augments cytotoxic activity 
of these cells via perforin, Fas and Trail-dependent mechanisms. Therefore, A3 receptor 
activation enhances NK cell activity and probably NK cell-mediated destruction of tumor cells 
(Harish et al., 2003). The expression of A3 receptor was also investigated in resting and 
activated lymphocytes (Gessi et al., 2004b). Activated human lymphocytes undergo a rapid 
induction of both transcript and protein of A3 receptors. The kinetics of this up-regulation 
revealed that even at earlier time points, the increase was present only in CD4+ cells, whereas it 
was not changed in CD8+ cells. Therefore, it is possible that in humans, as in mice (Hoskin et 
al., 2002), A3 receptors play an immunosuppressive role in CD8+ T cells, but their up-regulation 
in CD4+ cells strongly suggests that they might also be implicated in T helper cell activities. 
One method of increasing the number of A3 receptors on the cell membrane is to increase the 
accumulation of mRNA encoding the A3 subtypes. As evaluated by means of real-time RT-PCR 
experiments, activation of T cells with PHA rapidly increased the level of A3 message in the 
CD4+ subset, but not in the CD8+ cells. This increase in A3 receptor mRNA, which could occur 
as a result of an increase in transcription and/or an increase in mRNA stability, is likely to be 
responsible for the increased synthesis of receptor proteins as detected by means of binding and 
Western blot studies. The rapid up-regulation of A3 receptors functionally coupled to adenylyl 
cyclase in activated T cells may indicate another potential example of biological significance for 
adenosine-mediated responses in T cells.  
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An overexpression of A3 receptors has also been detected in lymphocytes of patients with 
colorectal cancer. Interestingly, the existence of A3 receptors was previously demonstrated on 
Jurkat cells, a human leukemic cell line, where they were associated with inhibition of adenylyl 
cyclase activity and calcium modulation (Gessi et al., 2001). Blood lymphocytes obtained from 
30 colorectal cancer patients showed a >3-fold overexpression of A3 receptors compared with 
blood cells from healthy donors, in line with the data found in tissues. No association was found 
with stage of the disease, tumor site, patient age, or gender. Even though the mechanism of this 
up-regulation are not known it is interesting that binding data from tissues, as in circulating 
blood cells, discriminate between small-sized adenomas and cancer, suggesting that A3 receptor 
may be a requirement for colorectal tumor progression. These receptors may represent, like 
those in neutrophils, tumoral markers due to their higher expression in comparison to that 
observed in healthy subjects. This suggests that peripheral blood cells mirror at the peripheral 
level the higher levels of the A3 receptor found in colorectal cancer. However the selectivity of 
the A3 receptor as a tumoral marker may be of only limited value because a similar 
phenomenon has been confirmed in patients with rheumatoid arthritis. Thus the A3 receptor was 
overexpressed in PBMC of patients with rheumatoid arthritis compared to healthy subjects and 
was directly correlated to an increase in NF-kB in the same cells (Madi et al., 2007). Similar 
data were found in phytohemagglutinin and lipopolysaccharide-stimulated PBMC from healthy 
subjects suggesting that receptor upregulation is induced by inflammatory cytokines controlling 
the expression of the A3 adenosine receptor transcription factor NF-kB (Madi et al., 2007). It 
seems that the A3 adenosine subtype found in PBMC obtained from peripheral blood may not 
represent a specific tumoral marker but more generally a marker for inflammation.  
In conclusion, it is well established that extracellular adenosine has the potential to be an 
important inhibitor of tumor cell destruction by NK and LAK cells within the 
microenvironment of solid tumors by signaling primarily through A2A and A3 adenosine 
receptors on the surface of T cells (Hoskin et al., 2008). However after the demonstration that 
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genetic deletion of immunosuppressive A2A and A2B receptors or their pharmacological 
inactivation can prevent the inhibition of anti-tumor T cells by the hypoxic tumor and facilitate 
full tumor rejection, several reviews focused on the relevance of A2A and in minor part of A2B 
adenosine subtypes to improve the effectiveness  of immune-based cancer therapies (Ohta et al., 
2006; Lukashev et al., 2007; Sitkovsky et al., 2008a,b). In contrast to the well described 
mechanisms by which A2A adenosine receptor signaling blocks T cell activation and effector 
function, little is known about the mechanism of A3 adenosine receptor-mediated T cell 
inhibition. Moreover, while the importance of A2A adenosine receptor signaling in adenosine-
mediated suppression of T cell responses has been confirmed using A2A adenosine receptor-
deficient mice (Lukashev et al., 2003), similar confirmatory studies have not yet been 
performed with A3 adenosine receptor deficient mice. Additional studies need to be performed 
in human lymphocytes as almost all the functional effects attributed to A3 receptor activation 
are derived from studies carried out in mice species (Figure 3). The identification of adenosine 
receptor subtypes and/or signal transduction pathways through which adenosine exerts its 
inhibitory effects on cell-mediated anti-tumor immune responses may allow for the 
development of novel “anti-adenosinergic” approaches that increase the effectiveness of 
therapeutic cancer vaccines and other immune-based cancer therapies. 
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Fig. 3-Effects of A3 adenosine receptors in lymphocytes 
Given the important species differences in the location and functional response to A3 receptors, only 
the effects obtained in human are in bold. 
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A3 adenosine receptor effects on monocyte-macrophage function 
In vivo and in vitro studies in animal systems led to the concept of the mononuclear-phagocyte 
system as a cell system involved in host defenses, phagocytosis, and antigen presentation and 
processing (Douglas, 1999). Following Metchnikoff's development of phagocyte theory, Wright 
described opsonins as factors in serum that facilitated phagocytosis. Aschoff defined the 
reticuloendothelial system as a cellular system in which tissue macrophages and monocytes share 
important functional characteristics, namely, phagocytic ability and adhesiveness to glass. 
Subsequently, the histologic development of silver stains by Del Rio-Hortega defined a type of 
macrophage-related cell in the brain, the microglia. In the mid-1960s, the late Zanvil Cohn and his 
collaborators carried out seminal studies of mononuclear phagocytes leading to concepts of 
macrophage differentiation, activation, secretion, and the relationship of macrophages to antigen 
presentation and processing (for further details see Douglas, 1999). 
Adenosine has been investigated as an endogenous regulator of monocyte-macrophage functions. 
The effects produced by A3AR activation of macrophages seem to indicate an anti-inflammatory 
effect of this adenosine subtype. For example, the A3ARs suppress TNF-α release induced by the 
endotoxin CD14 receptor signal transduction pathway from human monocytes and murine J774.1 
macrophages (Le Vraux et al., 1993; McWhinney et al., 1996). Moreover in a macrophage model 
the A3AR was the prominent subtype implicated in the inhibition of LPS-induced TNF-α production 
(Sajjadi et al. 1996). This effect was associated with changes in stimulation of the activator protein-1 
(AP-1) transcription factor, whereas it was independent of MAPKs, NF-kB, PKA, PKC and PLC. 
The inhibitory effect induced by the A3AR on TNF-α production was also assessed in A3KO mice 
where the A3 agonist was unable to reduce TNF-α levels in contrast to its effect in wild type animals 
(Salvatore et al., 2000). In contrast, in BV2 microglial cells the A3-mediated inhibition of LPS-
induced TNF-α expression was associated with the inhibition of LPS-induced activation of the PI3-
kinase/Akt and NF-kB pathways (Lee et al., 2006). Recently it has been reported that in mouse 
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RAW 264.7 cells the A3 subtype inhibits LPS-stimulated TNF-α release by reducing calcium-
dependent activation of NF-kB and ERK 1/2 (Martin et al., 2006). In contrast, in peritoneal 
macrophages, isolated from A3 KO mice, the ability of IB-MECA to inhibit TNF-α release was not 
altered in comparison to wild type mice (Kreckler et al., 2006). In this study, the inhibitory effect 
was exerted through the activation of A2A and A2B agonists as has been recently demonstrated in 
human monocytes (Zhang et al., 2005; Haskó et al., 2007). The discrepancy observed among these 
papers cannot be the consequence of species differences, since in both cases mouse cells were used. 
Other factors, including the source of the cells and/or the inflammatory stimulus used, may be 
responsible. However in spite of these contrasting results, one of the most likely therapeutic 
applications of the regulatory role of A3 activation on TNF-α release is in the treatment of arthritis. 
More recent studies show that A3AR agonists exert significant effects in different autoimmune 
arthritis models by suppression of TNF-α production (Baharav et al., 2005). The molecular 
mechanisms involved in the inhibitory effect of IB-MECA on adjuvant-induced arthritis include 
receptor downregulation and de-regulation of the PI3K-NF-kB signalling pathway (Fishman et al., 
2006; Madi et al., 2007). Thus, A3AR activation by IB-MECA inhibited macrophage inflammatory 
protein (MIP)-1α, a C-C chemokine with potent inflammatory effects, in a model of collagen-
induced arthritis, providing the first proof of concept of the adenosine agonists utility in the 
treatment of arthritis (Szabò et al., 1998). Other anti-inflammatory effects involving A3 receptors 
activation include inhibition of fMLP-triggered respiratory burst and tissue factor expression by 
human monocytes (Broussas et al., 1999, 2002). Recently, it has been reported that, adenosine may 
be involved in ventricular remodeling by stimulating Matrix metalloproteinase-9 (MMP-9) 
production in human macrophages following A3 receptor activation (Velot et al., 2008). MMP-9 
plays an important role in ventricular remodelling after acute myocardial infarction (MI). Adenosine 
enhanced MMP-9 production when macrophages were activated by hypoxia or Toll-like receptor-4 
ligands such as lipopolysaccharide, hyaluronan, and heparan sulfate. The effect of adenosine was 
replicated by the A3 agonist IB-MECA and inhibited by silencing the A3AR through the use of RNA 
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interference. Interestingly, it was found that MMP-9 expression was higher in blood cells from 
patients with acute MI compared with healthy volunteers with important implications for therapeutic 
strategies targeting adenosine receptors in the setting of MI (Velot et al., 2008).  
In conclusion as for the role of A3 receptors in the inhibition of TNF-α production in macrophages 
discrepant results have been obtained and not only due to the different species considered. For 
example some studies attributed reduction of TNF-α  to A3 receptors either in human and mouse 
species (Sajjadi et al., 1996; McWhinney et al., 1996), whilst other found this effect to be mediated 
essentially by A2A and in minor part by A2B without the involvement of the A3 receptors again in 
both human and mouse species (Zhong et al., 2005; Kreckler et al., 2006). Therefore it is difficult in 
this case to verify the relevance of the A3 receptor-induced cellular response when other adenosine 
subtypes like A2A and A2B are also activated. As for the effects exerted by the A3 subtype in human 
monocytes and macrophages it is possible to find support for an anti-inflammatory role for this 
receptor as attested by reduction of tissue factor, oxidative burst and perhaps TNF-α  release. Also 
the recent discovery of an increase in MMP9 supports a role for A3 agonists in the therapy of 
myocardial infarction (Velot et al., 2008) (Figure 4). 
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Fig. 4-Effects of A3 adenosine receptors in monocytes-macrophages 
Given the important species differences in the location and functional response to A3 receptors, only 
the effects obtained in human are in bold. 
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A3 adenosine receptor effects on dendritic cell function  
Dendritic cells are antigen-presenting cells specialized to activate naive T lymphocytes and initiate 
primary immune responses (Steinman, 1991; Hart, 1997; Banchereau,et al., 1998). Dendritic cells 
originate from hemopoietic stem cells and migrate into peripheral tissues. Dendritic cells reside in an 
immature form in unperturbed tissue, where they are capable of taking up antigens but weak at 
stimulating T cells. Under the influence of a variety of so-called danger signals including pathogens; 
dying cells; soluble CD40 ligand; cytokines such as tumor necrosis factor-α (TNF-α), interleukin 1 
(IL-1), and interleukin 6 (IL-6), or bacterial products such as LPS dendritic cells undergo a process 
of differentiation known as maturation. Thereafter, they migrate to the T-cell areas of secondary 
lymphoid organs. This maturation process is associated with reduced phagocytic and endocytic 
activity, increased membrane expression of major histocompatibility complex and co-stimulatory 
molecules, production of cytokines such as interleukin 12 (IL-12), and acquisition of potent T-cell-
stimulating functions. Depending on the conditions, dendritic cells can stimulate growth of a variety 
of T-cell subsets. In the presence of IL-12, they support the growth of Th1 cells, whereas with IL-4 
dendritic cells induce Th2-cell differentiation. In recent years it has become clear that A3 adenosine 
receptors play a role in regulation of various activities of dendritic cells. 
The expression and function of adenosine receptors in human dendritic cells has been investigated 
by using reverse transcriptase-polymerase chain reaction and functional experiments (Panther et al., 
2001). mRNA expression of the A3 receptor has been detected in immature dendritic cells together 
with A1 and A2A receptors.  Adenosine, IB-MECA and also the A1 agonist CHA, induced Ca2+ 
transients as well as actin polymerization and chemotaxis but only in immature dendritic cells. These 
findings suggest that adenosine may control proinflammatory activities of dendritic cells and 
regulate their accumulation at target sites. Maturation of dendritic cells is accompanied by a loss of 
the adenosine responses such as Ca2+ transients, actin polymerization, and migration. Unequivocal 
evidence of cell surface expression of the A3 receptor in immature dendritic cells was obtained from 
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[125I]ABMECA binding experiments. Saturation isotherms indicated a Bmax of approximately 300 
fmol/mg membrane protein, and competition for the radioligand of a variety of adenosine receptor 
ligands categorically identified the binding site as the A3 receptor (Fossetta et al., 2003). Moreover 
through fluorometric imaging plate reader (FLIPR)-based analysis of calcium mobilization it was 
shown that the A3 adenosine receptor is coupled to calcium mobilization in a pertussis toxin- 
dependent way. Interestingly these authors demonstrated that adenosine is much more potent at the 
A3 receptor than had been appreciated, being active in the low nanomolar range. Generally, 
adenosine has been regarded as a low potency agonist of the A3 receptor, with apparent affinities 
ranging from 300 nM to 1 µM (Fredholm et al., 2001). The presence of functional A3 receptors has 
been observed in XS-106, a mouse dendritic cell line, where they were coupled negatively to 
adenylyl cyclase and to stimulation of p42/p44 mitogen-activated protein kinase phosphorylation. 
Adenosine A3 receptor activation also inhibits lipopolysaccharide-induced TNF-α release from XS-
106 cells as already reported in macrophages (McWhinney et al., 1996; Dickenson et al., 2003). At 
present, the signal transduction pathway involved in adenosine A3 receptor-mediated inhibition of 
TNF-α release from XS-106 cells (and see above macrophages) is unclear. Inhibition of TNF-α 
release is usually associated with Gs-protein-coupled receptor-mediated cyclic AMP production. 
Interestingly, adenosine A3 receptors have been shown to induce an increase in intracellular calcium 
and potentiate Ca2+ currents via protein kinase A activation in A6 renal cells (Reshkin et al., 2000) 
and hippocampal CA3 pyramidal neuronal cells (Fleming and Mogul, 1997). In addition, activation 
of the adenosine A3 receptor stimulates cyclic AMP production in human eosinophils (Ezeamuzie 
and Philips, 2003). However, in XS-106 cells, Cl-IB-MECA did not stimulate cyclic AMP 
accumulation indicating that the adenosine A3 receptor is not directly coupled to Gs-protein/cyclic 
AMP accumulation in XS-106 cells. Finally, the transcript for the A3 adenosine receptor was 
elevated more than 100-fold in immature dendritic cells compared with monocyte precursors. A3 
receptor transcript was substantially diminished by LPS-induced maturation of immature dendritic 
cells. The strict dependence of A3 receptor expression on the immature cells suggests that the A3 
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receptor could also be involved in the maintenance of the immature phenotype, and its abrupt 
disappearance may be crucial for transition to a fully activated dendritic cell (Fossetta et al., 2003).  
The relevance of the A3 receptor over the other adenosine subtypes in immature human dendritic 
cells is attested to by different studies demonstrating a role for this receptor in the increase of 
intracellular calcium, actin polymerization and chemotaxis (Panther et al., 2001; Fossetta et al., 
2003) (Figure 5). However a loss of the A3 and an increase of the A2A receptor has been reported 
during maturation of dendritic cells. This switch has been interpreted as a protective effect of 
adenosine in the context of tissue injury as A2A activation plays an inhibitory role on dendritic cells 
migration. In this way adenosine could counterbalance inflammatory stimuli by delaying the arrival 
of mature dendritic cells to lymph nodes, thereby impairing the initiation of immune responses and 
reducing the potentially detrimental effects of chronic cell activation responsible for tissue damage 
and disease.  
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Fig. 5-Effects of A3 adenosine receptors in dendritic cells 
Given the important species differences in the location and functional response to A3 receptors, only 
the effects obtained in human are in bold. 
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Conclusion 
The data summarized in this chapter show that A3 receptors are present in immune cells and are 
indeed involved in the physiopathologic regulation of inflammatory and immune processes. 
However results from in vitro and in vivo studies in experimental animals suggest activation of the 
A3 subtype can be both pro or anti-inflammatory depending on:  
i) the cell type examined e.g. neutrophil, eosinophil, macrophage, T cell, dendritic cell;  
ii) the cellular model used e.g. in vitro or ex vivo; transgenic animals;  
iii) the response investigated e.g. degranulation, oxidative burst, migration, maturation, cytokine 
production; 
iv) the species considered e.g. human or animal; 
v) the presence and functional roles of other adenosine receptor subtypes. 
Even though it seems that in each cell type examined contrasting effects have been reported, the 
results reviewed here offer the background for possible new therapeutic strategies for a number of 
inflammatory conditions such as sepsis, asthma and autoimmune disorders including rheumatoid 
arthritis, Crohn’s disease and psoriasis. Indeed at the moment there are A3AR agonists in clinical 
development for rheumatoid arthritis. Unfortunately there are no A3AR antagonists in clinical 
development but a number of molecules are in biological testing as therapeutic agents for asthma 
and COPD, glaucoma, and stroke, waiting to enter the clinical arena (Baraldi et al. 2008). Future 
studies aimed at elucidating new effects of the A3 subtype in the modulation of important 
inflammatory responses in the different peripheral blood cells are likely to reveal exciting new 
potential therapeutic applications of A3 agonists and/or antagonists. 
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Modulation of MMP-9 in U87MG glioblastoma cells by A3 adenosine receptors 
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INTRODUCTION 
      Local invasive growth is one of the key features of primary brain tumors. Glioma is the most 
common primary adult brain tumor with poor prognosis because of the aggressive invasion of the 
surrounding normal brain. Although our understanding of glioma oncogenesis has steadily 
improved, the molecular mechanisms that mediate glioma invasion are still poorly understood. The 
degradation of extracellular matrix (ECM) which exerts biochemical and mechanical barriers to cell 
movement has been shown to be an important biological process in tumor invasion and metastasis 
[1]. ECM degradation and remodelling require the action of extracellular proteinases, among which 
the matrix metalloproteinases (MMPs) have been shown to play an essential role. Indeed MMPs are 
cation-dependent endopeptidases which have been implicated in the malignancy of gliomas [2]. In 
particular it has been shown that MMP-9 facilitates the invasion of glioblastoma cells in vitro and 
MMP-9 overexpression correlates with the malignant progression of gliomas in vivo [3], [4], [5] and 
[6]. On the basis of reports from several different laboratories, it has been generally concluded that 
the basal levels of MMP-9 in most cancer cell lines are usually low and that its expression can be 
induced by treatment of growth factors, cytokines, tumor promoters and oncogenes, through the 
activation of its gene promoter [7]. Several studies have identified signal transduction pathways 
involved in the regulation of MMP-9 expression in tumor cells [8]. A major mechanism through 
which signals from extracellular stimuli are transmitted to the nucleus involves activation of 
extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinase/stress-activated protein 
kinase (JNK/SAPK) and p38 mitogen-activated protein kinase (MAPK) [7], [9], [10] and [11]. 
Furthermore a critical role for PI3K/Akt signalling in the MMP-9 modulation has been described [9] 
and [12]. The human MMP-9 promoter contains several cis-acting regulatory elements that 
participate in the regulation of the MMP-9 gene expression, including sites that bind the 
transcription factors activator protein 1 (AP-1), nuclear factor-kappa B (NF-kB) and Sp1. In 
particular the AP-1 transcription complex appears to play an essential role in stimulating 
transcriptional activation of MMP-9 [10], [11] and [13]. 
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Adenosine (Ado) is a purine nucleoside which is released from metabolically active cells or is 
generated extracellularly by degradation of released ATP. It regulates a wide variety of 
physiological processes interacting with one or more of four known cell surface receptors named 
A1, A2A, A2B and A3 [14]. The development of potent A3 agonists and selective antagonists revealed 
that the A3 subtype plays a pivotal role in inflammation, in the ado-induced modulation of tumor 
cells biology [15], [16] and [17] and the A3 subtype has been found up-regulated in colorectal 
cancer [18]. Recently, we have demonstrated that ado stimulates proliferation of colon cancer cells 
and up-regulates under hypoxia the transcription factor hypoxia-inducible factor-1α (HIF-1α); this 
led to an increase in vascular endothelial growth factor (VEGF) and angiogenesis in melanoma, 
glioblastoma and colon carcinoma cells through A3 receptor activation [19], [20], [21] and [22]. 
This effect was also observed in pro-inflammatory and pro-atherosclerotic foam cells [23]. 
However, the involvement of ado in the regulation of MMP-9 in tumor cells have not been 
investigated by now. In this study we will use U87MG human glioblastoma cells as an in vitro 
model to evaluate the role of ado in the modulation of MMP-9 and the intracellular pathways 
involved. The main finding of this work is that ado increases MMP-9 protein levels in cellular 
extracts of U87MG cells through A3 receptors activation and phosphorylation of ERK1/2, JNK, Akt 
and AP-1. Furthermore it also increases extracellular MMP-9 levels in supernatants from U87MG 
cells; this effect is responsible for an increase of glioblastoma cell invasion. 
 
MATERIAL AND METHODS 
Materials 
U87MG glioblastoma cancer cells were purchased from American Type Culture Collection 
(Manassas, VA, USA). [3H]DPCPX (specific activity 120 Ci/mmol), was purchased by NEN 
Research Products, (Boston, MA, USA). [3H]ZM 241385 (specific activity 20 Ci/mmol), was 
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furnished by Tocris, (Boston, MA, USA). [3H]MRE 2029F20 (specific activity 123 Ci/mmol) and 
[3H]MRE 3008F20 (specific activity 67 Ci/mmol), were synthesized at Amersham International 
(Buckinghamshire, UK). MRE 2029F20, MRE 3008F20, DPA23 were synthesized by Prof. P.G. 
Baraldi (Department of Pharmaceutical Sciences, University of Ferrara, Italy). U0126 and SB 
202190 were from Promega (Milan, Italy). SH-5 was from Vinci-Biochem (Florence, Italy). 
Adenosine A3 receptors and MMP-9 small interfering RNA (siRNA) were from Santa Cruz 
Biotechnology, D.B.A. ITALIA s.r.l., (Milan, Italy). RNAiFect Transfection Kit was from Qiagen 
(Milan, Italy). NDGA was obtained from Calbiochem Inalco S.p.A. (Milan, Italy). Unless otherwise 
noted, all other reagents were purchased from Sigma (Milan, Italy). 
 
Cell cultures 
U87MG glioblastoma cancer cells were maintained in Dulbecco's modified Eagle's medium/Ham's 
F12 medium (DMEM/F12 medium) with 20% fetal calf serum, 2 mM l-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, at 37 °C in 5% CO2/95% air. All treatments to the cells with ado 
were carried out in the presence of the adenosine deaminase (ADA) inhibitor, erythro-9-(2-hydroxy-
3-nonyl)adenine (EHNA) 5 µM and those with ado agonists were performed in the presence of 
ADA. Cells viability was assessed through trypan blue assays and was not modified after treatments 
with ado or drugs. 
 
Real-time RT-PCR 
Total cytoplasmic RNA was extracted by the acid guanidinium thiocyanate phenol method. 
Quantitative real-time RT-PCR assay [19] of MMP-9 mRNA was carried out using gene-specific 
fluorescently labelled TaqMan MGB probe (minor groove binder) in a ABI Prism 7700 Sequence 
Detection System (Applied Biosystems, Warrington Cheshire, UK). For the real-time RT-PCR of 
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A1, A2A, A2B and A3 ado subtypes the assays-on- demand™ Gene expression Products 
Hs00181231_m1, Hs00169123_m1, Hs00386497_m1, Hs00181232_m1, were used, respectively 
(Applied Biosystems, Monza, Italy). Moreover curves of ado receptors cDNA plasmid standards 
with a range spanning at least six orders of magnitude (10−11–10−16 g/µl) were generated. These 
standard curves displayed a linear relationship between Ct values and the logarithm of plasmid 
amount [19]. Quantification of ado receptor messages in cancer cells was made by interpolation 
from standard curve of Ct values generated from the plasmid dilution series. For the real-time RT-
PCR of MMP-9 and TIMP-1 the assay-on-demand™ Gene expression Products Hs00234579_m1, 
Hs00171558_m1 were used, respectively. For the real-time RT-PCR of the reference gene the 
endogenous control human β-actin kits was used, and the probe was fluorescent-labeled with VIC™ 
(Applied Biosystems, Monza, Italy). 
Binding studies 
Binding assays were carried out according to Gessi et al. [19]. Saturation experiments of antagonist 
radioligands [3H]DPCPX (0.2–20 nM), [3H]ZM 241385 (0.2–20 nM), [3H]MRE 2029F20 (0.4–
40 nM) and [3H]MRE 3008F20 (0.3–30 nM) to label A1, A2A, A2B and A3 ado receptors, 
respectively, were carried out in U87MG cells. 100 µl of membrane homogenate (80–100 µg of 
protein assay−1) were incubated in duplicate, in a final volume of 250 µl in test tubes containing 
50 mM Tris–HCl buffer (10 mM MgCl2 for A2A, 10 mM MgCl2, 1 mM EDTA, 0.1 mM 
benzamidine for A2B and 10 mM MgCl2, 1 mM EDTA for A3) pH 7.4, with 10–12 different 
concentrations of each selective radioligand. Non-specific binding, defined as binding in the 
presence of 1 µM DPCPX, 1 µM SCH 58261, 1 µM MRE 2029F20, 1 µM MRE 3008F20 for A1, 
A2A, A2B and A3 ado receptors, respectively, at the KD value for each radioligand was ≈30–35% of 
total binding. Bound and free radioactivity were separated, after an incubation time of 120 min at 
4 °C, by filtering the assay mixture through Whatman GF/B glass-fiber filters using a cell harvester 
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(Packard Instrument Company, CT, USA). The filter bound radioactivity was counted on Top 
Count Microplate Scintillation Counter (efficiency 57%) with Micro-Scint 20. 
 
 
Western blotting analysis 
Whole cell lysates, prepared as described previously [21], were resolved on a 10% SDS gel and 
transferred onto the nitrocellulose membrane. Western blot analyses were performed as described 
previously using antibody against MMP-9 (Calbiochem Inalco, Milan, Italy) (1:200 dilution) in 5% 
non-fat dry milk in PBS 0.1% Tween-20 overnight at 4–8 °C. Recombinant active MMP-9 (83 kDa) 
was used as positive control (Calbiochem Inalco, Milan, Italy). Aliquots of total protein sample 
(50 µg) were analyzed using antibodies specific for phosphorylated (Thr183/Tyr185) p44/p42 
MAPK (1:5000 dilution) (Promega, Milan, Italy), phosphorylated (Thr180/Tyr182) p38 MAPK 
(1:1000 dilution) (Cell Signaling Technology, Milan, Italy), phosphorylated (Ser473) Akt/PKB 
(protein kinase B) (1:1000 dilution), phosphorylated (Thr183/Tyr185) SAPK/JNK, phosphorylated 
(Ser73) c-Jun (Cell Signaling Technology, Milan, Italy), and for A3 receptor (Aviva Antibody 
Corporation, Milan, Italy) (1 mg/ml dilution). Filters were washed and incubated for 1 h at room 
temperature with peroxidase-conjugated secondary antibodies against mouse and rabbit IgG (1:2000 
dilution). Specific reactions were revealed with the Enhanced Chemiluminescence Western blotting 
detection reagent (Amersham Corp., Arlington Heights, Ill.). Tubulin (1:250) was used to ensure 
equal protein loading. 
 
 Densitometry analysis 
The intensity of each band in immunoblot assay was quantified using a VersaDoc Imaging System 
(Bio-Rad, Milan, Italy). Mean densitometry data from independent experiments were normalized to 
the results in control cells. The data were presented as the mean ± S.E. 
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Treatment of cells with small interfering RNA (siRNA) 
U87MG cells were plated in six-well plates and grown to 50–70% confluence before transfection. 
Transfection of ado A3 receptor or MMP-9 siRNA, was performed at a concentration of 100 nM 
using RNAiFectTM Transfection Kit for 72 h [21]. A non-specific control ribonucleotide sense 
strand (5′-ACU CUA UCU GCA CGC UGA CdTdT-3′) and antisense strand (5′-dTdT UGA GAU 
AGA CGU GCG ACU G-3′) were used under identical conditions. 
Enzyme-linked immunosorbent assay (ELISA) 
The levels of MMP-9 protein secreted by the cells in the medium were determined by an ELISA kit 
(RayBio Elisa Kit, Tebu-bio, Milan, Italy). In brief, subconfluent cells were changed into fresh 
serum-free medium in the presence of solvent or various concentrations of ado and ado ligands for 
24 h. The medium was collected, centrifuged for 5 min at 900 g to remove floating cells and 
assayed for MMP-9 content by ELISA according to the manufacturer's instructions. The data were 
presented as mean ± SE from three independent experiments. 
Gelatin zimography 
Cells were incubated in serum-free medium for 24 h and the respective supernatants were used for 
the experiments. Twenty micrograms were mixed with sample buffer (0.5 M Tris–HCl pH 6.8, 10% 
glycerol, 2% SDS, 0.1% bromophenol blue) and separated on 10% SDS-polyacrylamide gels 
containing either gelatine from porcin skin (1 mg/ml). After electrophoresis, gels were washed for 
1 h in renaturing buffer (2.5% Triton X-100) and subsequently incubated overnight at 37 °C in 
50 mM Tris–HCl, 0.2 M NaCl, 5 mM CaCl2, 0.02% Brij 35 pH 7.5). Gels were stained with 0.3% 
Coomassie Brilliant blue and destained with 7% acetic acid methanol, 1% methanol and 7%  
Invasion assay 
Invasion was measured by assessment of the U87MG cells migration rate by using Cell Invasion 
Assay kit (Chemicon International, Milan, Italy). 2 × 105 U87MG cells were plated into the upper 
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well of the chamber in serum-free medium for 72 h, while the lower well was filled up to the top 
with MEM plus 10% FBS as chemoattractant. Treatment of the cells with ado, Cl-IB-MECA and 
inhibitors was carried out for 48 h. After incubation stained invasive cells were quantitated by 
dissolving them in 10% acetic acid and reading OD at 560 nm according to the manufacturer's 
instructions. 
Protein inhibitors 
U0126, SB202190, SH-5 specific inhibitors of ERK 1/2, p38 and Akt were used at a concentration 
of 1 µM according to previous experiments showing their specificity carried out in cancer cells [22]. 
SP600125, the JNK inhibitor was used at a dose of 1 µM according to its affinity and selectivity 
data [24]. Nordihydroguaiaretic acid (NDGA), the AP-1 inhibitor was used at a dose of 10 µM 
according to literature data [25]. MMP-9 inhibitor I was used at a dose of 50 nM [26]. 
Data analysis 
Binding studies were analyzed with the program LIGAND [27]. Statistical analysis was performed 
by means of analysis of variance (ANOVA) and the Dunnett's test. P < 0.05 was considered 
significant. 
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RESULTS 
Expression of ado receptors mRNA and protein in human U87MG glioblastoma 
cells 
First of all we examined the pattern of expression of ado receptors in U87MG glioblastoma cells. 
The mRNA level of ado receptors was examined through real-time RT-PCR experiments. As shown 
in Fig. 1A U87MG cells expressed all ado subtypes with the following rank order 
A2A > A2B > A1 > A3. At a protein level saturation assays with the A1 receptor antagonist 
[3H]DPCPX revealed the presence of A1 receptors with a KD value of 2.5 ± 0.3 nM and a Bmax value 
of 28 ± 1 fmol/mg of protein; saturation studies with the A2A antagonist [3H]ZM 241385 showed 
A2A receptors with a KD value of 2.0 ± 0.1 nM and a Bmax value of 110 ± 13 fmol/mg of protein; 
saturation experiments with the A2B antagonist [3H]MRE2029F20 detected A2B receptors with a KD 
value of 3.8 ± 0.5 nM and a Bmax value of 85 ± 9 fmol/mg of protein; saturation assays with the A3 
antagonist [3H]MRE3008F20 revealed A3 receptors with a KD value of 2.2 ± 0.40 nM and a Bmax 
value of 102 ± 10 fmol/mg of protein (Fig. 1B). 
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Figure.1 
 
 
 
 
 
 
 
 
 
 
Fig. 1. mRNA and protein expression of ado receptors in human U87MG glioblastoma cells. (A) Bar graph 
showing µg RNA/µg total RNA of human A1, A2A, A2B and A3 ado receptors evaluated through real-time RT-
PCR experiments. (B) Bar graph showing Bmax (fmol/mg of protein) of human A1, A2A, A2B and A3 ado 
receptors measured by means of binding experiments. Experiments were performed as described in Section 2. 
Values are the means and vertical lines S.E. of the mean of three separate experiments performed in triplicate. 
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Ado effect on MMP-9 mRNA in U87MG glioblastoma cells 
Initial experiments were carried out to evaluate the effect of ado on MMP-9 transcript levels in 
U87MG cells. After treatment of 6, 12, 24 and 48 h with the nucleoside (100 µM) we observed a 
time-dependent increase in MMP-9 mRNA of 1.5 ± 0.2, 1.8 ± 0.2, 2.5 ± 0.3 and 3.5 ± 0.4 fold, 
respectively (Fig. 2A). In order to identify which receptor subtype was involved in the ado-
mediated MMP-9 increase we incubated U87MG glioblastoma cells with high affinity A1, A2A, A2B 
and A3 ado analogues. The A1, A2A and A2B agonists, CHA, CGS 21680 and DPA23 respectively, 
did not affect MMP-9 increase whilst the A3 agonist Cl-IB-MECA 100 nM was able to induce a 
raise of 2.0 ± 0.3 fold of MMP-9 mRNA level, after 24 h of treatment, in U87MG glioblastoma 
cells. These results indicated that ado may increase MMP-9 mRNA through the involvement of A3 
receptors (Fig. 2B). Furthermore ado 100 µM and the A3 agonist Cl-IB-MECA 100 nM induced a 
modest stimulation of 1.6 ± 0.2 and 1.4 ± 0.2 fold of increase, respectively, of tissue inhibitor 
metalloproteinase-1 (TIMP-1) (Fig. 2C). The relative affinities of adenosine agonists as well as 
antagonists used in this study for the different adenosine receptor subtypes are provided in Table 1. 
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Figure.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Modulation of MMP-9 mRNA by ado in U87MG glioblastoma cells. (A) Time course of MMP-9 
mRNA expression in U87MG cells after treatment with ado 100 µM. (B) Effect of ado receptor agonists, 
100 nM CHA, 100 nM CGS 21680, 100 nM DPA23, 100 nM Cl-IB-MECA on MMP-9 mRNA induction 
in U87MG cells. (C) Effect of ado and Cl-IB-MECA on TIMP-1 mRNA expression in U87MG 
glioblastoma cells. Experiments were performed as described in Section 2. Values are the means and 
vertical lines S.E. of the mean of three separate experiments performed in triplicate. P < 0.05 compared 
with the control (cells incubated in the absence of treatment). MMP-9 mRNA control values at 6, 12, 24 
and 48 h were arbitrarily defined as 1.  
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Table 1.  
Affinity (Ki, nM) of selected adenosine receptor agonists and antagonists to A1, A2A, A2B and A3 adenosine 
receptors. 
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     Ado effect on MMP-9 protein levels in U87MG glioblastoma cells 
      Using an anti-MMP-9 antibody, that recognized both the pro and active forms of MMP-9 as 
bands migrating at 92 kDa and ≈78 kDa respectively, we found that Ado 100 µM induced a time-
dependent increase of both pro and active MMP-9 levels starting from 6 h and reaching a peak 
after 12–24 h of incubation (Fig. 3A and B). U87MG glioblastoma cells showed constitutive 
expression of the ≈78 kDa form of MMP-9, that was the active MMP-9 protein, as further 
verified by comparison with the recombinant active MMP-9, used as positive control (Fig. 3C). 
As the effect induced by ado on active MMP-9 was most evident we focused our attention on it. 
Treatment of the cells with ado in the range 0.01–100 µM for 24 h resulted in a dose-dependent 
increase of active MMP-9 with an EC50 of 3.5 ± 0.2 µM (Fig. 4A and B). By using a series of 
selective antagonists of A1, A2A, A2B and A3 ado receptors we observed that the nucleoside effect 
was abrogated in the presence of the A3 blocker MRE 3008F20, whilst was unaffected by 100 nM 
DPCPX, SCH 58261 and MRE 2029F20, A1, A2A, and A2B antagonists, respectively (Fig. 4C and 
D). To further verify the involvement of A3 receptors in the modulation of MMP-9 protein 
expression, we treated U87MG glioblastoma cells with the high affinity A3 receptor agonist Cl-
IB-MECA, in western blotting experiments (Fig. 5A). A3 receptor activation by Cl-IB-MECA, in 
the range of concentration 1–500 nM, produced a stimulatory effect on MMP-9 protein levels, 
with an EC50 of 10 ± 1 nM (Fig. 5B). Furthermore increasing concentrations of MRE 3008F20 
(0.05–100 nM) were able to inhibit MMP-9 protein increase, induced by a maximal dose 
(100 nM) of Cl-IB-MECA, with an IC50 of 1.3 ± 0.1 nM (Fig. 5C). To demonstrate more 
conclusively a role for A3 receptor in the adenosine-induced MMP-9 protein accumulation, we 
tried to knockdown A3 receptor expression using small interfering-(si)-RNA leading to a transient 
knockdown of the A3 receptor gene (siRNAA3). U87MG glioblastoma cells were transfected with 
non-specific random control ribonucleotides or with siRNAA3. As expected 72 h post 
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transfection, A3 receptor mRNA and protein levels of U87MG glioblastoma cells were 
significantly reduced (Fig. 5D and E, respectively). Therefore, at 72 h from the siRNA 
transfection we found that the stimulatory effect induced by a maximal dose of the A3 agonist 
was strongly reduced, suggesting that inhibition of A3 receptor expression is responsible for the 
block of Cl-IB-MECA-mediated MMP-9 increase (Fig. 5F and G) 
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                      Figure.3                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Modulation of pro and active MMP-9 protein levels by ado in U87MG glioblastoma cells. (A) Time 
course of MMP-9 protein levels in U87MG cells after treatment with ado 100 µM. On the left the 75 and 
100 kDa bands of the molecular weight marker are shown. (B) Densitometric quantification of MMP-9 
western blot is the mean ± S.E. values (N = 3); P < 0.05 compared with the control. MMP-9 protein 
control values at 6, 12, 24 and 48 h were arbitrarily defined as 1. (C) Increasing concentrations (0.1, 0.25, 
0.5 µg) of recombinant active MMP-9 (83 kDa) and endogenous pro and active MMP-9 in U87MG cells 
in the absence or presence of ado. 
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Figure.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Effect of ado and ado antagonists on MMP-9 protein levels in U87MG glioblastoma cells. (A and B) 
Immunoblot and relative dose-response curve of ado (0.01–100 µM) on MMP-9 protein levels, 
respectively. (C) Effect of ado 100 µM on MMP-9 protein levels and antagonism by 100 nM DPCPX, 
SCH 58261, MRE 3008F20 and MRE 2029F20. (D) Densitometric quantification of MMP-9 western blot 
is the mean ± S.E. values (N = 3); P < 0.05 compared with the control (cells incubated in the absence of 
treatment).  
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Figure.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Involvement of A3 receptor on ado-induced MMP-9 protein levels modulation in U87MG 
glioblastoma cells. (A and B) Immunoblot and relative dose-response curve of Cl-IB-MECA (1–500 nM) on 
MMP-9 protein levels, respectively. (C) Dose-response curve of antagonism by MRE 3008F20 (0.05–
100 nM) on 100 nM Cl-IB-MECA effect. Values are the means and vertical lines SE of the mean of three 
separate experiments performed in triplicate. (D) Relative A3 ado receptor mRNA quantification, related to β-
actin mRNA, and (E) A3 receptor protein level in U87MG cells after transfection with A3 siRNA for 72 h. (F) 
Effect of A3 receptors siRNA treatment on Cl-IB-MECA (100 nM) induction of MMP-9 in U87MG cells. (G) 
Densitometric quantification of MMP-9 western blot is the mean ± S.E. values (N = 3); P < 0.05 compared 
with the control.  
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 Intracellular pathways activated by ado A3 receptor to increase MMP-9 levels 
in U87MG glioblastoma cells 
To establish the intracellular pathways triggered by A3 receptors to stimulate MMP-9 protein 
increase in U87MG cells the effect of the A3 receptor agonist on MAPK and Akt activation was 
investigated. To this aim glioblastoma cells were pretreated for 30 min with 1 µM U0126, 
SB202190, SP600125, SH-5, specific inhibitors of ERK1/2, p38, JNK and Akt, respectively and 
subsequently stimulated with Cl-IB-MECA. As reported in Fig. 6A and B, U0126, SP600125 and 
SH-5 inhibitors at a concentration of 1 µM were able to inhibit the effect induced by the A3 agonist 
Cl-IB-MECA on MMP-9 protein levels whilst SB202190 did not, suggesting that ERK1/2, JNK and 
Akt but not p38 pathway were required for MMP-9 protein increase induced by A3 receptor 
activation. Furthermore, we observed that treatment of glioblastoma cells with Cl-IB-MECA for 6, 
12 and 24 h induced a time-dependent increase of ERK1/2, JNK and Akt phosphorylation (Fig. 6C–
E). Similar results were obtained with ado (Fig. 7A–C) and its effect was antagonized by MRE 
3008F20 and siRNAA3 supporting a role for A3 receptors in kinases phosphorylation (Fig. 7D–F). 
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Figure.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Involvement of MAPK and Akt kinases in A3 receptor-induced MMP-9 protein levels in U87MG 
cells. (A) Role of p38, Akt, ERK 1/2 and JNK inhibitors in MMP-9 modulation induced by Cl-IB-MECA 
50–100 nM. (B) Densitometric quantification of MMP-9 western blot is the mean ± S.E. values (N = 3); 
(C–E) Time course of Cl-IB-MECA 100 nM on ERK1/2 (C), JNK (D) and Akt (E) phosphorylation. 
Densitometric quantification of western blots is the mean ± S.E. values (N = 3); P < 0.05 compared with 
the control (cells incubated in the absence of treatment). 
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Figure.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Time course of ado 100 µM on ERK1/2 (A), JNK (B) and Akt (C) phosphorylation and antagonism by 
MRE 3008F20 and siRNA of A3 receptors on the ado effect (12 h) on ERK1/2 (D), JNK (E) and Akt (F) 
phosphorylation. Densitometric quantification of western blots is the mean ± S.E. values (N = 3); P < 0.05 
compared with the control (cells incubated in the absence of treatment, or with MRE 3008F20, or with 
siRNAA3 alone, defined as 100).  
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AP-1 involvement in the A3 receptor-mediated increase of MMP-9 levels in 
U87MG glioblastoma cells. 
The activator protein-1 (AP-1) transcription complex appears to play an essential role in stimulating 
transcriptional activation of MMP-9. In order to verify the involvement of AP-1 in the A3 ado 
receptor-induced MMP-9 protein increase, we performed western blotting experiments in the 
presence of ado 100 µM and the A3 agonist Cl-IB-MECA 500 nM, in combination with the AP-1 
antagonist NDGA 10 µM. As reported in Fig. 8A and B the AP-1 inhibitor was able to reduce the 
ado A3 receptor-mediated effect on MMP-9 levels. Furthermore, to evaluate in more detail the 
effect of A3 receptor activation on the phosphorylation of c-Jun, a major subunit of AP-1, 
glioblastoma cells were treated with increasing concentrations of ado and Cl-IB-MECA. As shown 
in Fig. 8C-F both ado and Cl-IB-MECA were able to raise p-c-Jun protein levels in a dose-
dependent way with an EC50 of 4.5 ± 0.3 µM and 9.0 ± 0.8 nM, respectively. When the A3 receptor 
subtype was blocked with the A3 antagonist MRE 3008F20, the stimulatory effect induced by Cl-
IB-MECA on p-c-Jun was reverted, suggesting again the involvement of A3 receptors in this effect 
(Fig. 8G and H). 
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Figure.8 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Involvement of AP-1 in A3 receptor-induced MMP-9 protein levels in U87MG cells. (A) Detection of 
MMP-9 protein by western blotting experiment in the presence of ado (100 µM) or the A3 agonist Cl-IB-
MECA (500 nM) in combination with the AP-1 antagonist NDGA 10 µM. (B) Densitometric quantification 
of western blots is the mean ± S.E. values (N = 3); P < 0.05 compared with the control. (C–F) Immunoblots 
and relative dose-response curves of ado (0.01–100 µM) and Cl-IB-MECA (1–500 nM) on p-c-Jun protein 
levels, respectively. (G) Effect of Cl-IB-MECA 100 and 500 nM on p-c-Jun levels and antagonism by MRE 
3008F20 100 nM on Cl-IB-MECA effect. (H) Densitometric quantification of MMP-9 western blot is the 
mean ± S.E. values (N = 3); P < 0.05 compared with the control.  
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MMP-9 levels in supernatants from U87MG glioblastoma cells by ELISA and 
gelatin zimography assays 
In order to investigate whether A3 receptor activation was also able to increase MMP-9 protein 
levels in the supernatants from human U87MG glioblastoma cells, ELISA assays, recognizing both 
the latent and active MMP-9 forms, were performed. After 24 h of treatment ado and the A3 agonist 
Cl-IB-MECA, were able to induce a stimulatory effect of 162 ± 14% and 175 ± 15% on MMP-9 
levels in cancer cells that was antagonized by both A3 antagonist and siRNA treatment (Fig. 9A). 
The A1, A2A and A2B adenosine analogues did not modulate MMP-9 levels. Furthermore, MMP-9 
activity was evaluated in the conditioned medium using zymography. A band corresponding to the 
active 82 kDa MMP-9 form was detected and was increased after exposure of U87MG glioblastoma 
cells to the A3 agonist Cl-IB-MECA 100–500 nM and Ado 10–100 µM for 24 h (Fig. 9B and C). 
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Figure.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. A3 receptor-mediated increase of MMP-9 in supernatants of U87MG cells. (A) Effect of ado, Cl-IB-
MECA, A3 antagonists and A3 silencing on MMP-9 levels by ELISA assay. Values are the mean ± S.E. 
values (N = 3); P < 0.05 compared with the control. (B) Effect of 100, 500 nM Cl-IB-MECA and 10, 100 µM 
ado on MMP-9 activity by gelatin zymography. Experiments were performed as described in Section 2. (C) 
Densitometric quantification of gelatine zimography. Values are the means and vertical lines S.E. of the mean 
of three separate experiments performed in triplicate. P < 0.05 compared with the control.  
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   A3 receptor effect on invasiveness of U87MG glioblastoma cells 
    To assess whether increased production of MMP-9 protein by A3 receptor activation resulted also 
in increased invasion of tumor cells, an in vitro cell invasion assay was done. We cultured 
U87MG glioblastoma cells on invasion chambers in the absence and in the presence of Ado 
100 µM and the A3 agonist Cl-IB-MECA 100 nM. After 48 h of cultures in the presence of Ado 
and the A3 agonist, the invasive capacity of U87MG cells was highly increased (160 ± 20% and 
180 ± 30% of control, respectively) and the effect was reduced by the addition of the A3 
antagonist MRE 3008F20, A3 silencing, MMP-9 inhibitor I and MMP-9 silencing. This suggests 
that A3 receptors and MMP-9 play a role in modulating glioblastoma invasiveness (Fig. 10A). 
The stimulatory effect induced by both Ado and Cl-IB-MECA was also antagonized by U0126, 
SH-5 and SP600125 indicating the involvement of ERK1/2, Akt and JNK in the invasion of 
U87MG cells (Fig. 10B). 
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Figure.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Modulation of U87MG cell invasion. (A) Effect of 100 µM ado and 100 nM Cl-IB-MECA on 
U87MG cell invasion and antagonism by 100 nM MRE 3008F20, A3 receptor silencing, MMP-9 silencing 
and 50 nM MMP-9 inhibitor I. (B) Effect of ERK 1/2, Akt and JNK inhibitors in A3 receptor-mediated cell 
invasion. Experiments were performed as described in Section 2. Values are the means and vertical lines S.E. 
of the mean of three separate experiments performed in triplicate. P < 0.05 compared with the control.  
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Discussion 
MMPs play a major role in promoting tumor metastasis. In particular overexpression of MMP-9 has 
been shown to be associated with the progression and invasion of several tumors including gliomas 
[3]. Although malignant gliomas rarely metastasize outside of the central nervous system, they are 
extremely invasive tumors. Several works have reported that glioblastomas produce significantly 
higher levels of MMP-9 than do lower-grade tumors and normal brain tissue [7] and [28]. 
Ado depending on the extracellular concentration and expression of different ado receptor subtypes 
is known as a modulator of cell proliferation, apoptosis and angiogenesis (for review see Ref. [16]). 
Only few experimental works have focused on the effects of ado in MMP modulation and have 
been performed in cells of the immune system. In fact it has been reported that ado inhibits 
neutrophil-produced MMP-9 via A2A receptors, it increases MMP-9 in macrophages through A3 
subtypes [29] and [30] and it suppresses MMP-9 production under hypoxic conditions in human 
monocyte-derived dendritic cells via A2B receptors [31]. In the current study, we sought to 
determine the involvement of ado in the regulation of MMP-9 production in U87MG glioblastoma 
cells. The main finding of this work is that ado increases MMP-9 levels through activation of A3 
receptors, ERK 1/2, JNK, Akt, AP-1 and is responsible for an increase in cell invasion. First of all 
we evaluated mRNA and protein levels of ado receptors in U87MG cells. Our results from real-time 
RT-PCR experiments showed that all ado receptors were expressed in glioblastoma cells with the 
following order A2A > A2B > A1 > A3. This mRNA order of expression did not match exactly the 
protein order found by binding assays that was A2A > A3 > A2B > A1. This was due to the low 
mRNA level of A3 receptors in comparison to its high protein amount, already observed in different 
cell systems [19] and [32]. This supports the emerging evidence that mRNA expression patterns are 
necessary but are by themselves insufficient for the quantitative description of biological systems. 
This evidence includes discoveries of post-transcriptional mechanisms controlling the protein 
translation rate or the half-lives of specific proteins or mRNAs [33] and [34]. However it is also 
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known that the gene promoter region of A3 receptors is rich in putative binding sites for ubiquitous 
transcription factors including AP-1, SP-1, EF-1A. These ubiquitous factors may be responsible for 
the widespread, low level of A3 mRNA expression observed [35]. In this particular case it could be 
speculated that c-Jun, stimulated by A3 receptors in U87MG cells, may be involved in negative 
feedback mechanisms to regulate A3 mRNA expression in response to high MMP-9 and cell 
invasion levels. Other transcription factors such as NF-kB and CREB interacting with the A3 gene 
promoter have been demonstrated to be involved in the overexpression of A3 receptors in peripheral 
blood cells of patients with rheumatoid artritis [36]. 
As uncontrolled activation of MMP-9 is potentially dangerous in a cellular environment, enzyme 
expression is tightly regulated at the transcriptional and/or translational level. Therefore we started 
to evaluate the effect of ado on MMP-9 transcription in U87MG cells. We found that the nucleoside 
was able to increase in a time-dependent manner the expression of MMP-9 mRNA starting from 
6 h, with the maximal effect observed after 12–24 h. The effect of ado was replicated by the A3 
ligand Cl-IB-MECA, but not by A1, A2A and A2B agonists suggesting the involvement of A3 
receptors. Furthermore we found that both ado and the A3 agonist induced a modest increase of 
TIMP-1 expression levels, suggesting the existence of a regulatory loop to compensate for MMP-9 
production. This was observed also in THP-1 macrophages by Velot et al. [30]. However like in 
THP-1 cells also in U87MG cells its low increase is probably insufficient to counterbalance the 
raised expression of MMP-9, induced by A3 receptor activation [30]. A reduced level of both MMP-
9 and TIMP-1 levels have been detected also in lungs and in the bronchoalveolar lavage fluid of A3 
receptors deficient mice suggesting that the A3 plays a regulatory role in their production [37]. Like 
most MMPs, MMP-9 is secreted as a latent zymogen, requiring activation in the extracellular milieu 
or on the cell surfaces to be catalytically competent [38] and [39]. However it has been also 
reported that some cellular types e.g. microvascular endothelial cells or tumor cells are capable of 
accumulating active gelatinase B in the cytoplasm or in membrane vesicles [40], [41] and [42] or 
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that specific cell-MMP interactions may occur such as binding of MMP-9 to CD44 [43]. Evidence 
of constitutive activation of MMP-9 in U87MG cells was suggested by expression of the active 
form of MMP-9 in cellular extracts of glioblastoma cells. Similar results have been obtained in 
different types of cancer cell lines including DU145 (prostate androgen-independent carcinoma), 
SK-NEP-1 (adult-derived anaplastic Wilms’ tumor), A431 (squamous cell carcinoma), Wit 49 
(Wilms’ tumor cell line), A549 (non-small cell lung carcinoma) and LNCaP (prostate androgen-
dependent carcinoma) [42]. Ado increased, in glioblastoma cells, the intracellular levels of both 
latent and active MMP-9 with a major effect on the second one. The conclusion that the effects of 
ado on MMP-9 protein were mediated through A3 receptors was supported by the observation that 
the stimulatory effects of this nucleoside on MMP-9 protein were mimicked by the A3 receptor 
agonist Cl-IB-MECA, and inhibited by the A3 receptor antagonist MRE 3008F20. In particular, the 
potencies of these drugs were in agreement with their inhibitory equilibrium binding constants (Ki) 
observed in binding experiments for the ado A3 receptor [44]. Furthermore, the A3 receptor-induced 
MMP-9 protein increase was blocked following the inhibition of A3 receptor expression at the 
mRNA and protein levels, by the RNA interference approach. 
MMP-9 gene expression can be activated via a number of signal transduction pathways including 
those involving ERK1/2, p38, JNK and PKB/Akt [7] and [9]. Ado has been demonstrate to activate 
some of these signalling molecules in different systems and cellular models through the activation 
of A3 receptors (for review see Ref. [45]). In particular an increase in ERK1/2 phosphorylation has 
been reported initially by Schulte and Fredholm [46] in transfected CHO cells and then it has been 
confirmed in other systems like microglial and colon carcinoma cells [19] and [47]. Several studies 
have also indicated the ability of A3 receptors to activate PKB/Akt. This has been observed in rat 
basophilic leukemia 2H3 mast cells, in cardiomyocytes, in melanoma and colon carcinoma cells 
[20], [22], [48] and [49]. As for p38 a link with ado A3 receptors has been observed in rat basophilic 
leukemia 2H3 cells, colon carcinoma cells and rat hearts [22], [50] and [51]. In contrast the effect of 
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A3 receptor activation on JNK has not been investigated. Our results show that stimulation of 
MMP-9 by A3 receptor activation was abrogated by inhibitors of ERK1/2, JNK and Akt but not of 
p38, suggesting that more than one signalling pathway is involved in the MMP-9 modulation 
induced by A3 receptor activation. Indeed, Cl-IB-MECA and ado-mediated an increase in the 
phosphorylation of ERK1/2, JNK and Akt kinases confirming that they belong to the signaling 
pathways utilized by the nucleoside following A3 receptor stimulation. In particular it has been 
reported that JNK is necessary to phosphorylate c-Jun proteins and it is well known that the AP-1 
transcription complex appears to play an essential role in stimulating transcriptional activation of 
MMP-9 [7] and [13]. In its active form AP-1 complex may comprise homodimers of c-Jun or 
heterodimers between c-Fos, c-Jun and ATF2 [52]. Furthermore activation of ERK1/2 has been 
shown to induce c-Jun expression and phosphorylation, indicating cross-talk between ERK1/2 and 
JNK pathways in the regulation of c-Jun activity [8] and [53]. We found that MMP-9 regulation by 
A3 ado receptor activation was blocked after treatment with the AP-1 inhibitor; c-Jun, was also 
increased by ado and Cl-IB-MECA and this effect was antagonized by MRE 3008F20 suggesting 
the involvement of A3 ado receptor. We demonstrated that A3 receptor activation induced an 
increase of active MMP-9 as shown by ELISA and gelatine zymography experiments carried out on 
the supernatants obtained from U87MG cells, according to data showed by Velot et al. in 
macrophages [30]. 
Finally, as for the physiological relevance of the A3 receptor-mediated stimulation of MMP-9 we 
found that Cl-IB-MECA was responsible for an increase of the invasive ability of U87MG cells. 
This effect was dependent by modulation of MMP-9, exerted through A3 receptors activation and 
ERK1/2, JNK, Akt and AP-1 phosphorylation. Interestingly it was reported that MMP-9 inhibition 
might be useful for treating the invasiveness of brain tumors. Furthermore the antisense MMP-9 
vector or adenovirus expressing antisense MMP-9 decreased the PMA-induced migration and 
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invasion of glioblastoma cells [54]. Interestingly the increase induced by adenosine in cell invasion 
has been previously reported also in breast cancer cells [55] and [56]. 
It is well known that the A3 receptor plays an important role in regulating normal and tumor cell 
growth [16]. Elegant in vivo studies by Fishman's group showed the efficacy of A3 agonists in 
various tumor-bearing animals, supporting the utilization of A3 agonists to treat cancer [57]. In 
particular melanoma, colon, prostate and hepatocellular carcinomas were reduced in in vivo animal 
models by IB-MECA or Cl-IB-MECA [17], [57] and [58]. Importantly in these studies, the 
combined treatment of IB–MECA with the specific agents cyclophosphamide, 5-fluorouracil and 
taxol respectively, resulted in an enhanced antitumor effect. On the other hand, it has been reported 
that in U87MG glioblastoma cells under hypoxic conditions, Cl-IB-MECA induced up-regulation 
of hypoxia-inducible factor 1 (HIF-1) alpha and VEGF supporting a role for A3 antagonists as a 
novel approach for the treatment of glioblastomas [21]. A possible explanation for these different 
results may be that cell response to a given A3 agonist is determined by a plethora of factors, 
including agonist concentration and affinity, receptor density, interaction between different 
adenosine receptors expressed on the cell surface, cell type and the cell microenvironment. 
Furthermore ado effects on MMP-9 and cell invasion not necessarily shall to occur during 
carcinogenesis. For example, it has been demonstrated that the in vivo administration of Ado 
reversed cirrhosis and liver dysfunction and that one of the mechanisms involved in this effect was 
through an increase in collagenolytic activity [59]. Accordingly the results of this work, revealing a 
role of A3 receptor in the increase of glioblastoma cell invasion by stimulation of MMP-9, adds a 
new function to the complex role of A3 receptors in tumor biology and need to be verified in in vivo 
experiments. 
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